SCODiA Report by MLBI Lab

Single-Cell Atlas of the Colon Cancer Microenvironment: Immune Dysregulation, Stromal Remodeling, and Therapeutic Targets

This report provides a comprehensive single-cell analysis of human colon cancer, comparing tumor tissue with adjacent normal tissue. Key findings reveal significant shifts in cell population composition, particularly the expansion of aneuploid tumor epithelial cells and changes in immune and stromal cell subsets. We observe a profoundly altered tumor microenvironment characterized by extensive pro-tumorigenic cell-cell interactions, widespread metabolic reprogramming, and prominent immune evasion mechanisms. The identified molecular markers and pathways offer critical insights into disease progression and highlight several promising therapeutic targets.

Contents

0. Dataset overview
1. UMAP Visualization of Single-Cell RNA-seq Data Colored by Key Metadata
2. Overall Celltype_subset Marker Expression Analysis
3. Genomic Copy Number Variation (CNV) Analysis in Colonic Tumor Epithelium
4. CNV-Enhanced UMAP Visualization of Cell Types, Ploidy, Condition, and Sample
5. Minor Cell Type Population Analysis in Colon Tumor vs. Adjacent Normal Tissue
6. Analysis of T Cell Subset Population Changes in Colon Cancer
7. Macrophage Subset Population Analysis in Colon Tumor vs. Adjacent Normal Tissue
8. Differential T cell Subset Populations in Colon Tumor vs. Adjacent Normal Tissue
9. Differences in Macrophage Subpopulations Between Colon Tumor and Adjacent Normal Tissues
10. Ploidy Population Analysis of Tumor-Origin and Unassigned Cells in Colon Cancer
11. Colon Tumor Microenvironment: Cell-Cell Interaction Patterns
12. Cell-Cell Interaction Analysis in Colon Tissue: Normal vs. Tumor Conditions
13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Colon Tissue
14. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
15. Intestinal Epithelial Cell의 종양 특이적 표면 마커 분석
16. Macrophage Condition-Specific Surfaceome Markers in Colon Tumor
17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
18. CD4+ T cell Condition-Specific Surfaceome Markers in Colon Tumor Microenvironment
19. Dysregulation of Cell Cycle Pathway Genes in Tumor-Associated Intestinal Epithelial Cells
20. Intestinal Epithelial Cell Gene Ontology Analysis: Diploid vs. Aneuploid and Tumor vs. Adjacent Normal States
21. Colon Cancer Microenvironment: Gene Set Enrichment Analysis across Major Cell Types
22. Discussion
23. Query List

0. Dataset overview

데이터셋 요약

• 이 데이터셋은 32660개의 세포와 22103개의 유전자로 구성된 단일 세포 RNA 시퀀싱 데이터입니다.
• 인간 대장(Colon) 조직에서 유래했으며, Tumor 및 Adj_normal의 두 가지 조건이 포함되어 있습니다.
• 세포 타입은 T cell, Intestinal Epithelial cell, B cell 등 다양한 수준(major, minor, subset)으로 분류되어 있습니다.
• Intestinal Epithelial cell이 종양 기원 세포 타입으로 지정되어 있습니다.
• 세포는 Aneuploid 또는 Diploid로 판별된 ploidy_dec 정보도 포함합니다.

주요 Precomputed 결과

• 세포-세포 상호작용 (CCI): 조건 및 샘플별 CellPhoneDB 결과가 저장되어 있습니다.
• 차등 발현 유전자 (DEG): 각 celltype_minor에서 한 조건을 다른 조건과 비교한 결과가 있습니다.
• 유전자 세트 농축 분석 (GSEA): 각 celltype_minor에서 조건 비교를 통해 유전자 세트 농축 결과가 저장되어 있습니다.
• 유전자 온톨로지 (GSA/GO): 각 celltype_minor에서 조건 비교를 통해 GO 결과가 저장되어 있습니다.
• 이수성 (Ploidy): 세포 수준의 이수성 추정 라벨(Aneuploid/Diploid)이 obs['ploidy_dec']에 저장되어 있습니다.
• 복제 수 변이 (CNV): CNV 추정치는 obsm['X_cnv']에 매트릭스 형태로 저장되어 있습니다.

분석 가능한 세포 타입

• DEG, GSEA, GSA/GO 분석은 다음 celltype_minor 그룹에 대해 수행 가능합니다: B cell, Endothelial cell, Fibroblast, ILC, Intestinal Epithelial cell, Macrophage, Plasma cell, T cell CD4+, T cell CD8+.

1. UMAP Visualization of Single-Cell RNA-seq Data Colored by Key Metadata

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP (Uniform Manifold Approximation and Projection) plots, visualizing the 32,660 single cells from colon tissue (human) based on their gene expression profiles. The UMAPs are colored by various metadata features including condition (Tumor vs. Adj_normal), sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. This comprehensive visualization serves to assess data integration quality, confirm cell type annotations, and identify major patterns of cellular heterogeneity and disease-associated differences.

Visual Summary

Condition and Sample Distribution

• Condition: The UMAP colored by condition shows a significant degree of intermixing between cells from "Adj_normal" (maroon) and "Tumor" (purple) conditions across many clusters. However, certain clusters exhibit a clear enrichment for either "Tumor" or "Adj_normal" cells, indicating condition-specific cellular populations or states. For instance, the large cluster in the lower-right appears predominantly "Tumor", while some smaller peripheral clusters are enriched for "Adj_normal".
• Sample: The sample plot reveals that cells from different samples (e.g., SMC01-N, SMC01-T, etc.) are generally well-integrated across the UMAP space. This indicates that potential batch effects originating from individual samples are largely mitigated, allowing for more robust comparisons between biological conditions rather than technical variations.

Cell Type Hierarchy and Annotation Quality

• Cell type (Major, Minor, Subset): The UMAPs colored by celltype_major, celltype_minor, and celltype_subset demonstrate a clear and hierarchical organization of cell types.
• At the celltype_major level, distinct and well-separated clusters are observed for key cell types such as Intestinal Epithelial cells (orange), T cells (light blue), Myeloid cells (light green), Stromal cells (teal), B cells (maroon), and Endothelial cells (red).
• Progressing to celltype_minor and celltype_subset resolutions, these major clusters further resolve into finer, biologically meaningful sub-populations (e.g., T cell CD4+, T cell CD8+ within T cells; Enterocyte, Goblet cell within Intestinal Epithelial cells). This indicates high-quality and granular cell type annotation.
• The proportion of "unassigned" cells (purple) is low and these cells are scattered, suggesting that the vast majority of cells have been successfully classified.

Ploidy Status

• Ploidy (ploidy_dec): The ploidy_dec UMAP is particularly striking. It shows a large, distinct cluster predominantly composed of "Aneuploid" cells (maroon), while the majority of other clusters are "Diploid" (yellow). There are also scattered "Unclear" cells (purple). This pattern is highly significant given the data context of human colon tissue and a "Tumor origin celltype" of Intestinal Epithelial cell.

Biological Interpretation

The UMAP visualizations provide crucial insights into the cellular landscape of colon tissue and its changes in the tumor microenvironment:

1. Tumor Microenvironment Heterogeneity: The partial segregation of "Tumor" and "Adj_normal" cells, alongside their intermixing, suggests that while some cell populations are unique to or enriched in tumor samples, there are also common cell types whose states might be altered in the tumor context, or shared immune/stromal populations. The ploidy_dec map provides a direct link to the tumor cells themselves.
2. Robust Cell Type Annotation: The clear separation and hierarchical organization of cell types from major to subset levels strongly validate the quality of cell type assignments. This robust annotation forms a reliable foundation for downstream analyses such as differential gene expression, cell-cell interaction inference, and pathway enrichment, ensuring that findings are attributed to correctly identified cell populations.
3. Identification of Tumor Cells via Ploidy: The ploidy_dec plot serves as a powerful validation of tumor cell identification. The observation of a large, distinct cluster of "Aneuploid" cells strongly corresponds to the malignant Intestinal Epithelial cells, which are known to undergo chromosomal instability and polyploidy in cancer [1]. This aneuploid cluster prominently overlaps with the Intestinal Epithelial cell clusters seen in the celltype_major and celltype_minor plots. This clear delineation of tumor cells from diploid normal cells (immune, stromal, and normal epithelial cells) is critical for understanding tumor-specific biology.

Annotation Notes

The UMAP embeddings and cell type annotations appear robust and well-resolved, with clear separation of distinct cell populations. The successful integration of cells from multiple samples, minimal "unassigned" cell clusters, and the clear separation of aneuploid tumor cells further support the reliability of the dataset for subsequent in-depth analyses. The hierarchical annotation from major to subset cell types provides valuable resolution for investigating specific cellular functions and interactions within the tumor microenvironment.

---

References:

1. Aneuploidy in Cancer: https://www.genecards.org/Search/Keyword?query=Aneuploidy%20cancer

2. Overall Celltype_subset Marker Expression Analysis

[Analysis Visualization Results]...

Analysis Overview

This dot plot presents the expression profiles of a curated set of marker genes across the various celltype_subset populations identified in the single-cell RNA-seq data from human Colon tissue. Each dot's size represents the fraction of cells within a given subset that express a particular gene, while its color intensity indicates the mean expression level of that gene. The markers displayed were specifically selected as surfaceome genes highly characteristic of each cell type, serving to validate and refine the accuracy of the cell type annotations.

Visual Summary

The visualization effectively highlights distinct molecular signatures for the majority of celltype_subset populations.

• Many cell subsets display clear, highly expressed, and frequently detected marker genes (large, dark red dots) that are largely specific to their respective groups. These specific markers are often accentuated by the red bounding boxes around clusters of genes, strongly supporting the unique identity of these cell types based on their transcriptomic profiles.
• For instance, genes like ASCL2 for Crypt cells, DLL4 for Endothelial cells, CPA3 for Mast cells, and MZB1 for Plasma cells serve as highly characteristic and defining markers.
• While most markers show high specificity, some genes exhibit broader expression across closely related cell types (e.g., IL2RG in various ILCs and T cells). This is biologically expected and reflects shared functional components or lineage relationships.
• The overall pattern demonstrates that the existing celltype_subset annotations are robustly supported by distinct marker gene expression, indicating a reliable initial clustering and annotation process.

Biological Interpretation

The observed marker gene expression patterns across the celltype_subset populations are largely consistent with established biological knowledge, thereby reinforcing the confidence in these cell type annotations.

• Intestinal Epithelial Cells (IECs): Given that the Intestinal Epithelial cell is identified as the Tumor origin celltype, accurate annotation of its subsets is paramount.
• Crypt cells are clearly defined by high expression of ASCL2, EPHB2, OLFM4, and AXIN2. These genes are well-known as crucial regulators of intestinal stem cell maintenance and Wnt signaling, confirming their identity as stem-like epithelial cells found in the crypts GeneCards: ASCL2.
• Enterocytes show strong expression of FABP1, VIL1, and CDX1, consistent with their primary role in nutrient absorption and differentiation along the intestinal villi GeneCards: VIL1.
• Goblet cells are identified by MUC13 and TFF3, genes involved in mucus production and epithelial barrier protection GeneCards: TFF3.
• Paneth cells express LYZ and MMP7, known for their production of antimicrobial peptides that contribute to innate immunity in the gut GeneCards: LYZ.
• Microfold cells (M cells) show specific expression of PRAP1, aligning with their specialized function in antigen sampling.
• Tuft cells express SMOC2, consistent with their recognized chemosensory and immunomodulatory functions in the gut.

Immune Cells:

• B cell (Breg) and B cell (MZ) subsets show POU2F2, a key transcription factor regulating B cell development and function GeneCards: POU2F2.
• Plasma cells are robustly identified by MZB1, JCHAIN, XBP1, and TNFRSF17 (BCMA), which are all canonical markers of antibody-secreting, terminally differentiated B cells GeneCards: TNFRSF17.
• Macrophage (M1) displays CTSH and CCL20, indicative of a pro-inflammatory phenotype. Other macrophage subsets (M2A, M2B, M2C, M2D) also exhibit distinct marker profiles, with LYZ broadly expressed across macrophages.
• Mast cells are clearly identified by CPA3 (Carboxypeptidase A3) and TPSAB1 (Tryptase alpha/beta 1), key proteases stored in mast cell granules GeneCards: CPA3.
• Dendritic cell (Plasmacytoid) shows expression of LILRA4 and IRF7, highly specific markers for pDCs and their roles in antiviral responses GeneCards: LILRA4.
• ILC1, ILC2, ILC3 (NCR-), ILC3 (NCR+), and LTI cells display specific combinations of markers such as GATA2, GATA3, RORA, and IL2RG, consistent with their diverse roles in innate immunity and development.
• T cell subsets (Cytotoxic, Tfh, Th1, Th17, Th2, Th22, Treg) exhibit distinct molecular profiles:
• T cell (Cytotoxic) expresses GZMB, a hallmark effector molecule of cytotoxic T lymphocytes GeneCards: GZMB.
• T cell (Tfh) is marked by TNFRSF4 (OX40) and KLF6, implicated in germinal center T cell help.
• T cell (Th1) is associated with STAT4, a key transcription factor in Th1 differentiation.
• T cell (Th17) is characterized by RORA, a critical transcription factor for Th17 development.
• T cell (Th2) shows GATA3, a master regulator of the Th2 lineage.
• T cell (Treg) shows TNFRSF18 (GITR), an important costimulatory receptor for regulatory T cells.

Stromal and Endothelial Cells:

• Fibroblasts exhibit strong expression of extracellular matrix (ECM) components like LUM (Lumican), DCN (Decorin), COL1A1 (Collagen Type I Alpha 1 Chain), and COL3A1 (Collagen Type III Alpha 1 Chain), validating their role in tissue architecture and repair GeneCards: DCN.
• Endothelial cells and Endothelial tip cells express DLL4 and ANGPT2, genes crucial for angiogenesis and vascular development GeneCards: ANGPT2.
• Lymphatic Endothelial cells are specifically identified by PROX1, a master regulator essential for lymphatic endothelial cell identity GeneCards: PROX1.
• Smooth muscle cells are characterized by contractile proteins such as ACTA2 (Alpha-Smooth Muscle Actin), MYH11 (Myosin Heavy Chain 11), and TAGLN (Transgelin) GeneCards: ACTA2.

Annotation Notes

The celltype_subset annotations within this dataset appear robust and highly reliable, being strongly supported by the specific and distinct marker gene expression patterns observed. The clear delineation of most cell subsets by unique transcriptional profiles, particularly within the emphasized gene clusters, indicates that these populations are well-separated and confidently identifiable. No significant anomalies or highly ambiguous cell groups are apparent from this dot plot, suggesting a high quality of cell type annotation for these single-cell RNA-seq data, which is foundational for all subsequent biological interpretations and downstream analyses.

3. Genomic Copy Number Variation (CNV) Analysis in Colonic Tumor Epithelium

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to characterize copy number variations (CNVs) within the designated tumor-origin Intestinal Epithelial cell population, along with unassigned cells, from human colon single-cell RNA-seq data. The cells were grouped by individual sample, and CNV estimates (log2(CNR)) were visualized across genomic regions. Additionally, a summary of significantly amplified regions, including their frequency across tumor samples, was generated to highlight recurrent genomic gains.

Visual Summary

Main CNV Heatmap (log2(CNR))

The heatmap illustrates the log2(CNR) values across the genome for cells grouped by their inferred ploidy status (Diploid or Aneuploid), sample identifier, and condition (T for Tumor, N for Adj_normal).

• Aneuploid Tumor Samples: The majority of tumor samples (e.g., SMC01-T, SMC02-T, SMC04-T, SMC08-T, SMC09-T, SMC14-T, SMC15-T, SMC18-T, SMC20-T) are classified as Aneuploid. These samples exhibit extensive and recurrent patterns of genomic alterations, including distinct regions of amplification (red color indicating positive log2(CNR)) and deletion (blue color indicating negative log2(CNR)) across multiple chromosomes. Prominent recurrent amplifications are visually apparent on regions of chromosome 7, 8, 13, and 19/20. Recurrent deletions are particularly noticeable on chromosome 18.
• Diploid Samples: Samples classified as Diploid, which include all Adj_normal samples (e.g., SMC01-N, SMC03-N, SMC04-N) and a subset of Tumor samples (e.g., SMC10-T, SMC11-T, SMC16-T, SMC17-T, SMC21-T, SMC22-T, SMC23-T, SMC24-T, SMC25-T), show minimal to no significant CNV activity, consistent with a stable diploid genome.

Summary of Significantly Amplified Regions

The accompanying summary heatmap and bar plot provide a more focused view of frequently amplified cytogenetic bands across the tumor samples.

• Sample-Specific Amplification Frequencies: The summary heatmap shows the proportion of cells within each tumor sample that exhibit significant amplification for specific cytogenetic bands. Several tumor samples (e.g., SMC04-T, SMC08-T, SMC09-T, SMC11-T, SMC14-T, SMC16-T, SMC17-T, SMC20-T, SMC21-T, SMC22-T) display high frequencies of amplification (indicated by darker blue shades) in common genomic regions.
• Recurrent Amplified Regions (Bar Plot): The bar plot quantifies the overall frequency of significant amplification for each cytogenetic band across all tumor samples. The most frequently amplified regions are:
• 19q13.43-21q21.3 with the highest frequency (0.76).
• 7p14.1-7p11.2 (EGFR) and 7p12.3-7q11.23 (EGFR), both showing a high frequency of 0.59. These regions are known to contain the epidermal growth factor receptor (EGFR) gene.
• 6q27 also at a frequency of 0.59.
• 7q22.1-7q31.1 at a frequency of 0.53.

Other notable amplified regions include 1q21.3-1q22, 4q13.3-4q21.21, 8p11.23-8q12.3 (containing LSM1, DDHD2), and 8q24.3 (containing EIF3E, INTS8, GSDMD). The region 9p24.1-9p19.3, which includes the tumor suppressor gene CDKN2A, shows lower and less consistent amplification frequencies across samples compared to the highly recurrent amplifications.

Biological Interpretation

The CNV patterns observed in the Intestinal Epithelial cell and unassigned cell populations from tumor samples provide strong evidence of genomic instability, a fundamental hallmark of cancer. The clear distinction between the Aneuploid and Diploid classifications aligns well with expected genomic alterations in tumor versus normal cells, respectively.

• EGFR Amplification: The consistent and high-frequency amplification of regions on chromosome 7 containing the EGFR gene (7p14.1-7p11.2 and 7p12.3-7q11.23) is a highly significant finding. EGFR amplification is a well-established oncogenic driver in numerous solid tumors, including colorectal cancer. It leads to overexpression of the EGFR protein, resulting in hyperactivation of downstream signaling pathways that promote cell proliferation, survival, and metastasis. GeneCards: EGFR
• Recurrent 19q Amplification: The frequent amplification of 19q13.43-21q21.3 is also notable. This region harbors several genes whose gain in copy number has been associated with cancer progression in various contexts, including colorectal cancer, often impacting cell cycle regulation and apoptosis. PubMed search: 19q amplification colorectal cancer
• Genomic Heterogeneity: The presence of some tumor samples (e.g., SMC11-T, SMC16-T) within the Diploid group suggests potential genomic heterogeneity within the tumor microenvironment or between different tumors. While many tumors are aneuploid, a subset can maintain a near-diploid karyotype, or the inferred ploidy might reflect the overall cellular composition of the analyzed sample, potentially including non-epithelial tumor-associated cells that were not fully excluded by the cell type filter, or less genomically unstable tumor clones.
• The analysis effectively highlights tumor-specific CNV landscapes, identifying key genomic gains that are likely driving forces in the development and progression of these colon tumors. These specific alterations in gene dosage can have profound effects on the expression of oncogenes and tumor suppressor genes.

Annotation Notes

• The ploidy_dec annotation effectively segregates cells into Aneuploid and Diploid groups, which largely corresponds to the observed burden of CNVs in the heatmap. This validates the utility of the ploidy inference for broadly characterizing the genomic state of individual cells.
• The inclusion of unassigned cells alongside Intestinal Epithelial cell populations for CNV analysis implies that these unassigned cells are presumed to share similar genomic characteristics with the tumor-origin cells. Their similar visual CNV patterns within the Aneuploid group suggest they indeed represent a neoplastic or similarly affected population, rather than being distinct non-neoplastic cells.
• The observation of Diploid tumor samples warrants further investigation. This could be due to genomic stability in certain tumor subclones, limitations in CNV detection sensitivity for subtle changes, or the presence of a significant proportion of non-epithelial cells in these particular tumor samples which may not have been fully accounted for by the cell type filtering.

4. CNV-Enhanced UMAP Visualization of Cell Types, Ploidy, Condition, and Sample

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱 데이터를 기반으로 생성된 AnnData 객체의 세포들을 CNV(복제수 변이) 정보를 포함하는 UMAP 임베딩 공간에 시각화한 결과입니다. 각 플롯은 세포들을 주요 세포 유형(celltype_major), 보조 세포 유형(celltype_minor), 배수성 상태(ploidy_dec), 샘플의 조건(condition: Tumor/Adj_normal), 및 개별 샘플(sample)에 따라 색상으로 구분하여, CNV 패턴이 세포 정체성과 질병 상태에 어떻게 반영되는지 탐색합니다. UMAP 임베딩은 CNV 정보가 통합되어 생성되었으므로, CNV가 유사한 세포들이 서로 가깝게 배치됩니다.

Visual Summary

• 전반적인 UMAP 구조: UMAP 플롯은 크게 두 개의 주된 클러스터와 몇몇 작은 분리된 클러스터를 보여줍니다. 이는 세포들이 CNV 패턴을 기반으로 뚜렷하게 분리됨을 시사합니다.

세포 유형별 분포 (celltype_major, celltype_minor):

• Intestinal Epithelial cell (장 상피세포): UMAP의 한쪽 끝에 있는 뚜렷한 클러스터(주로 주황색 계열)를 형성하며, 이 클러스터는 주로 소수 세포 유형 플롯에서 "Intestinal Epithelial cell"로 확인됩니다. 이는 AnnData 컨텍스트에서 종양 기원 세포 유형으로 명시된 것과 일치합니다.
• 면역/기질 세포: T cell, B cell, Myeloid cell, Stromal cell, Endothelial cell 등 비상피 세포들은 주로 UMAP 중앙의 더 큰, 이질적인 클러스터에 함께 뭉쳐 있습니다. 이들은 CNV 패턴 측면에서 상피 세포 클러스터와는 구별됩니다.
• 일부 세포 유형의 분리: T cell (CD4+, CD8+)은 이질적인 클러스터 내에서도 비교적 밀집된 영역을 형성하며, Fibroblast, Macrophage 등도 특정 영역에 분포하는 경향이 있습니다.

배수성 상태별 분포 (ploidy_dec):

• Aneuploid 세포: UMAP 플롯의 한쪽 끝에 뚜렷한 클러스터(주로 진한 빨간색)를 형성합니다. 이 Aneuploid 클러스터는 위에서 언급된 Intestinal Epithelial cell 클러스터와 매우 높은 공간적 중첩을 보입니다.
• Diploid 세포: UMAP의 더 크고 중앙에 위치한 클러스터(주로 밝은 노란색)를 지배하며, 주로 면역 및 기질 세포 유형과 겹칩니다.
• "Unclear" 세포: 소수의 세포들이 Aneuploid 및 Diploid 클러스터 사이에 산재되어 있거나 작은 독립 클러스터를 형성합니다.

조건별 분포 (condition):

• Tumor 세포: "Aneuploid" 세포가 밀집된 클러스터와 높은 중첩을 보이며, 주로 Intestinal Epithelial cell 클러스터에 집중되어 있습니다. 이는 종양 세포가 비정상적인 CNV 패턴(이수성)을 가질 가능성이 높음을 시사합니다.
• Adj_normal 세포: "Diploid" 세포가 밀집된 클러스터와 중첩되며, 주로 면역 및 기질 세포 유형을 포함하는 큰 클러스터에 분포합니다.

샘플별 분포 (sample):

• 각 샘플은 UMAP 공간에 분산되어 있지만, 특히 "Tumor"로 끝나는 샘플들 (예: SMC01-T, SMC02-T 등)은 Aneuploid/Intestinal Epithelial cell 클러스터에 주로 기여합니다.
• "N"으로 끝나는 샘플들 (예: SMC01-N, SMC02-N 등)은 Diploid/면역 및 기질 세포 클러스터에 더 많이 분포합니다.
• 일부 샘플은 두 클러스터 모두에 기여하며, 이는 종양 미세환경에 침윤된 면역/기질 세포와 종양 세포의 존재를 반영합니다. 종양 샘플 내에서도 여러 CNV 클론 또는 이질성이 관찰될 수 있습니다.

Biological Interpretation

이 CNV-aware UMAP은 콜론 조직의 단일 세포 데이터를 분석할 때 CNV가 세포 정체성과 질병 상태를 구분하는 데 강력한 역할을 함을 명확히 보여줍니다.

1. 종양 세포의 식별: 가장 중요한 관찰은 "Intestinal Epithelial cell" (종양 기원 세포 유형으로 정의됨)이 주로 "Aneuploid" 상태이며 "Tumor" 조건과 강하게 연관된 UMAP 클러스터를 형성한다는 것입니다. 이는 CNV 분석이 암세포를 비암세포로부터 효과적으로 식별하고 분리할 수 있음을 입증합니다. 암은 종종 염색체 수의 비정상적인 변화(이수성)와 같은 광범위한 CNV를 특징으로 합니다 (참고: PubMed search for "aneuploidy cancer").
2. 종양 미세환경의 구성: UMAP의 주요한 Diploid 클러스터는 T cell, B cell, Myeloid cell, Stromal cell, Endothelial cell 등 다양한 면역 및 기질 세포 유형으로 구성되어 있습니다. 이들은 "Adj_normal" 샘플과 "Tumor" 샘플 모두에서 발견되며, 이는 이들 세포가 종양 미세환경의 필수적인 구성 요소임을 나타냅니다. 이들 세포는 일반적으로 정상 배수체(Diploid)이므로 CNV 패턴으로 인해 종양 세포와 명확하게 분리됩니다.
3. 세포 유형 어노테이션의 신뢰성: CNV 정보를 포함한 임베딩이 세포 유형, 배수성, 조건 간의 뚜렷한 분리를 보여주므로, 현재의 세포 유형 어노테이션이 CNV 상태와 잘 일치하며 신뢰할 수 있음을 시사합니다. 특히 "Intestinal Epithelial cell"이 종양 세포의 주요 클러스터를 형성하는 것은 이 세포 유형이 종양의 원천임을 지지하는 강력한 증거입니다.
4. 샘플 간 이질성: 샘플별 플롯은 CNV 프로파일에 따른 환자 간 이질성을 보여줍니다. 특정 종양 샘플(예: SMC01-T, SMC02-T)은 이수성 상피 클러스터에 풍부하게 기여하는 반면, 다른 샘플은 분포가 다를 수 있습니다. 이러한 이질성은 종양 진화 또는 다양한 치료 반응의 잠재적 요인을 반영할 수 있습니다.

Annotation Notes

• 이 CNV-aware UMAP은 세포 유형 어노테이션의 품질을 평가하고, 종양 세포와 비종양 세포를 명확하게 구분하는 데 매우 유용합니다.
• "Tumor" 조건과 "Aneuploid" 상태의 강한 연관성은 종양 유래 Intestinal Epithelial cell을 효과적으로 식별하는 데 CNV 추정치가 성공적으로 사용되었음을 나타냅니다.
• CNV 정보가 UMAP 임베딩에 통합됨으로써, 세포 클러스터링이 세포의 생물학적 특성(특히 종양성 변환)을 더 잘 반영하게 됩니다.
• "unassigned" 세포나 "Unclear" ploidy_dec가 일부 클러스터를 형성하는 것을 확인할 수 있는데, 이는 추가적인 조사를 통해 이들 세포의 정체성이나 CNV 상태를 더 명확히 정의할 필요가 있음을 시사합니다.

5. Minor Cell Type Population Analysis in Colon Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a comparative population bar plot of minor cell types derived from single-cell RNA-seq data, contrasting samples from Colon Tumor tissue with those from Adjacent Normal tissue. The plot illustrates the relative proportion of each minor cell type within individual samples, providing insights into the cellular composition shifts associated with colorectal tumorigenesis. The "Intestinal Epithelial cell" is specified as the tumor origin cell type, which is a key reference for interpreting the observed changes.

Visual Summary

The visualization comprises two panels, one for "Adj_normal" samples and one for "Tumor" samples, each displaying stacked bar plots representing the percentage contribution of various minor cell types per individual sample.

• Intestinal Epithelial Cell Expansion in Tumor: The most striking observation is a substantial increase in the proportion of "Intestinal Epithelial cell" (orange-yellow) in most "Tumor" samples compared to "Adj_normal" samples. In many tumor samples, this cell type constitutes over 60-80% of the total cellular population, whereas in adjacent normal tissue, it represents a more modest proportion (e.g., 20-40%).
• Reduction of T-cell Populations in Tumor: Both "T cell CD4+" (light blue) and "T cell CD8+" (darker blue) populations appear to be relatively reduced in most "Tumor" samples when compared to "Adj_normal" tissue. In normal tissue, T cells are a prominent immune component, often accounting for a significant portion of the lymphoid compartment.

Changes in Other Immune Cells:

• "Plasma cell" (light green) populations show a general decrease in their relative abundance in tumor samples.
• "Macrophage" (light yellow) populations exhibit variable changes, maintaining a significant presence or sometimes appearing slightly increased in proportion in certain tumor samples (e.g., SMC05-T, SMC14-T) compared to normal tissue.
• "B cell" (dark red), "Dendritic cell" (red), "NK cell" (pale yellow), and "ILC" (light orange) generally remain at lower proportions in both conditions, though their relative contribution often shifts slightly.
• Stromal Cell Dynamics: "Fibroblast" (orange) populations are consistently present in both conditions and appear to be slightly more prominent in some tumor samples, consistent with the expected stromal remodeling in cancer. "Endothelial cell" (red-orange) and "Smooth muscle cell" (pale green) also contribute to the stromal compartment but in smaller proportions.
• Sample Heterogeneity: While "Adj_normal" samples show relatively consistent cell type proportions, "Tumor" samples exhibit greater heterogeneity in their cellular composition, particularly in the extent of "Intestinal Epithelial cell" dominance and the presence of other immune and stromal components.

Biological Interpretation

The observed shifts in cell type populations provide critical insights into the remodeling of the colonic tissue microenvironment during tumorigenesis.

1. Malignant Epithelial Expansion: The dramatic increase in "Intestinal Epithelial cell" proportion in tumor samples is consistent with the definition of this cell type as the "Tumor origin celltype" in colon tissue. This reflects the uncontrolled proliferation of malignant epithelial cells, which is a hallmark of cancer. These cells likely represent the tumor bulk, outcompeting other cell types in terms of cell numbers within the tumor microenvironment (TME). The precomputed ploidy and CNV data (obs['ploidy_dec'] and obsm['X_cnv']) further support the characterization of these expanded epithelial cells as cancerous.
2. Immune Evasion and Suppression: The relative decrease in T cell populations, particularly CD4+ and CD8+ T cells, in the tumor microenvironment suggests potential immune evasion mechanisms at play. CD8+ T cells are crucial for directly killing cancer cells, and their reduction might indicate impaired anti-tumor immunity. The decrease in plasma cells, which are antibody-producing B cell derivatives, could also point to an altered humoral immune response within the TME. These changes are characteristic features of an immunosuppressive TME, where tumor cells can escape detection and destruction by the immune system. PubMed: Immune Evasion in Cancer
3. Myeloid Cell Plasticity in Tumor: Macrophages, while showing variable changes, often contribute significantly to the TME. Tumor-associated macrophages (TAMs) can adopt pro-tumoral phenotypes (e.g., M2-like) that promote tumor growth, angiogenesis, and metastasis, rather than anti-tumor immunity. Their persistent or increased presence despite other immune cell reductions highlights their complex and often detrimental role in cancer progression. GeneCards: Macrophage Markers
4. Stromal Remodeling: The presence and occasional increase of fibroblasts in tumor samples underscore the role of cancer-associated fibroblasts (CAFs) in shaping the tumor stroma. CAFs are critical components of the TME, contributing to extracellular matrix remodeling, secreting growth factors, and promoting immunosuppression and tumor progression. PubMed: Cancer-Associated Fibroblasts

Clinical or Translational Implications

The distinct shifts in cellular composition between colon tumors and adjacent normal tissue have several potential clinical and translational implications:

• Biomarker Identification: The profound changes in the relative proportions of "Intestinal Epithelial cells" and immune cells (e.g., T cells, plasma cells) could serve as diagnostic or prognostic biomarkers. Quantifying these shifts, perhaps through spatial proteomics or imaging techniques, could help stratify patients or monitor disease progression.
• Therapeutic Targeting of the Tumor Microenvironment: The observed reduction in T cell populations and the likely presence of pro-tumoral macrophages and fibroblasts highlight potential targets for TME-focused therapies. Strategies aiming to reverse T cell exhaustion, re-activate anti-tumor T cell responses (e.g., immune checkpoint blockade), or deplete/re-educate TAMs and CAFs could be explored.
• Understanding Immune Response to Therapy: Monitoring changes in these cell populations after therapeutic interventions could provide insights into treatment efficacy and mechanisms of resistance. For example, successful immunotherapy might lead to an increase in activated T cells within the tumor, which would be visible in such population plots.
• Insights into Tumor Heterogeneity: The sample-to-sample variability observed in tumor samples suggests that colorectal tumors are heterogeneous in their cellular composition, which could influence treatment responses. Further stratifying tumors based on their TME cellular profiles might lead to more personalized therapeutic approaches.

6. Analysis of T Cell Subset Population Changes in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the proportional distribution of T cell subsets (minor cell types) across individual samples from both adjacent normal colon tissue and colon tumor tissue. The plot illustrates the relative abundance of different lymphocytic populations, including CD4+ T cells, CD8+ T cells, Innate Lymphoid Cells (ILC), and Natural Killer (NK) cells, within the broader "T cell" major cell type compartment. This comparison aims to highlight shifts in the immune landscape associated with the tumor microenvironment.

Visual Summary

The visualization presents two main panels: "Adj_normal" and "Tumor," each displaying stacked bar plots for individual samples. Each bar represents a sample, with its height summing to 100% of the T cell major population. Different colors within each bar denote the proportion of various minor cell types: ILC (burgundy), NK cell (orange), T cell CD4+ (light orange), T cell CD8+ (light yellow), and unassigned (teal, though very minimal in these plots).

Key observations:

• Adjacent Normal (Adj_normal) Samples: In adjacent normal tissue, ILCs constitute a notable proportion, typically ranging from approximately 10% to 25% of the T cell compartment across most samples. NK cells are generally scarce. CD4+ T cells and CD8+ T cells together account for the vast majority, often showing a relatively balanced or slightly CD4+-dominant composition.
• Tumor Samples: In contrast, tumor tissue samples generally show a marked reduction in the proportion of ILCs compared to adjacent normal tissue, often falling below 10%. NK cell proportions remain low. A striking observation is the apparent enrichment of CD4+ T cells in many tumor samples, where they frequently represent a larger proportion of the T cell compartment than CD8+ T cells. While CD8+ T cells are present, their relative proportion often appears reduced compared to CD4+ T cells in the tumor microenvironment. There is considerable inter-sample heterogeneity, but the overall trend of ILC reduction and relative CD4+ T cell enrichment in the tumor is consistent across many samples.

Biological Interpretation

The observed shifts in T cell subset populations provide insights into the immune landscape of colon cancer.

1. Shift in CD4+ vs. CD8+ T cell balance: The relative enrichment of CD4+ T cells over CD8+ T cells in the tumor microenvironment (TME) is a significant finding. While CD8+ T cells are critical for direct anti-tumor cytotoxicity, CD4+ T cells have diverse functions. An increased proportion of CD4+ T cells in tumors could represent an influx of T helper (Th) cells that support anti-tumor responses (e.g., Th1) or, conversely, an accumulation of immunosuppressive regulatory T cells (Tregs) or other pro-tumorigenic Th subsets (e.g., certain Th17 subsets). Given that celltype_subset includes Tregs, this differential abundance merits further investigation into the specific CD4+ T cell phenotypes present in the TME to understand their functional implications. PubMed Search: CD4 T cell subsets in colon cancer
2. Reduced ILCs in Tumor: Innate Lymphoid Cells (ILCs), particularly ILC3s, are abundant in the gut and play crucial roles in maintaining intestinal homeostasis, regulating inflammation, and interacting with the microbiota. The reduction in ILCs within the tumor context suggests a disruption of the normal innate immune environment. This reduction could compromise tissue integrity, alter immune surveillance, or impact the local inflammatory balance, potentially contributing to tumor progression or immune evasion. GeneCards: ILC3 (ILC definition often relies on IL7R expression, though ILCs are heterogeneous)
3. Low NK cell presence: The consistently low proportion of NK cells in both adjacent normal and tumor tissues in this dataset might indicate that NK cells are not a predominant lymphocytic population in this colon context or that their infiltration is limited, which could have implications for innate anti-tumor immunity.

These proportional changes suggest that the colon tumor microenvironment actively reshapes the infiltrating T cell compartment, potentially favoring conditions that promote immune escape rather than effective anti-tumor immunity.

Clinical or Translational Implications

The altered composition of T cell subsets in colon tumors carries several clinical implications:

• Prognostic Value: A higher CD4+:CD8+ T cell ratio in the TME, especially if driven by Tregs, is often associated with poorer prognosis in various cancers, including colorectal cancer. The observed shift suggests potential immune suppression.
• Immunotherapy Response: The dominance of CD4+ T cells (requiring further sub-typing to discern Th1 vs. Treg) and the reduction of ILCs could influence the efficacy of immunotherapies. For instance, if Tregs are enriched, strategies to deplete Tregs or reverse their suppressive function might be beneficial. Similarly, understanding the reasons for ILC depletion could open avenues for restoring innate immune functions.
• Biomarker Discovery: The specific T cell subset ratios or the presence/absence of certain ILC populations could serve as biomarkers for patient stratification, predicting disease progression, or guiding treatment selection.
• Target Identification: Identifying the mechanisms driving the observed shifts (e.g., specific chemokines attracting CD4+ T cells, or factors suppressing ILCs) could reveal novel therapeutic targets for modulating the immune microenvironment in colon cancer.

7. Macrophage Subset Population Analysis in Colon Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional distribution of different macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual samples, comparing adjacent normal colon tissue ("Adj_normal") with colon tumor tissue ("Tumor"). This provides insight into the polarization state of macrophages within the tumor microenvironment (TME) and normal tissue, which is crucial given their diverse roles in inflammation, tissue homeostasis, and cancer progression.

Visual Summary

The bar plots display the relative proportions of five macrophage subsets (M1, M2A, M2B, M2C, M2D) for each sample, grouped by condition (Adj_normal and Tumor). Each bar represents a single sample, and the colored segments indicate the percentage of each macrophage subtype within the total macrophage population for that sample.

1. Adj_normal Samples:

• Macrophage (M1) (dark red) and Macrophage (M2A) (orange) appear to be substantial components in many adjacent normal samples, often contributing to a significant portion of the total macrophage population.
• Macrophage (M2B) (light yellow) is also consistently present, often constituting a large fraction, sometimes dominating over M1 and M2A in certain samples.
• Macrophage (M2C) (light green) and Macrophage (M2D) (teal) are generally present in smaller proportions across adjacent normal samples, though M2D shows some variability.

2. Tumor Samples:

• A striking shift is observed in the tumor microenvironment compared to adjacent normal tissue. Macrophage (M2B) (light yellow) becomes the overwhelmingly dominant subset in nearly all tumor samples, often comprising over 50% and sometimes approaching 80-90% of the total macrophage population.
• While Macrophage (M1) (dark red) remains present, its relative proportion appears reduced in many tumor samples compared to its prevalence in adjacent normal samples.
• Macrophage (M2A) (orange) also appears to be proportionally reduced in tumor samples compared to adjacent normal tissue.
• Macrophage (M2C) and Macrophage (M2D) remain minor populations in the tumor context, similar to their presence in adjacent normal tissue, although their overall relative contribution becomes even smaller due to the expansion of M2B.

Biological Interpretation

Macrophages are highly plastic immune cells that can differentiate into various functional phenotypes, broadly categorized as M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor, tissue repair). The observed shift in macrophage subset populations from adjacent normal colon tissue to tumor tissue indicates a significant reprogramming of the macrophage compartment within the tumor microenvironment.

• Dominance of M2B Macrophages in Tumors: The most prominent finding is the substantial increase in the relative abundance of Macrophage (M2B) in tumor samples. M2B macrophages are generally characterized by immune regulation and can be induced by immune complexes and Toll-like receptor (TLR) agonists. They are known to produce high levels of IL-10 and IL-6, which can suppress anti-tumor immunity and promote tumor growth and metastasis [1]. Their significant expansion suggests a strong pro-tumorigenic and immunosuppressive environment within the colon tumors.
• Reduced M1 and M2A Macrophages: The relative decrease in M1 and M2A macrophage proportions in tumors is also notable. M1 macrophages are typically associated with cytotoxic functions against tumor cells and promotion of Th1 immune responses. M2A macrophages are often involved in allergic responses and parasitic infections but also contribute to tissue repair and fibrosis, which can sometimes aid tumor progression, but less directly in immune suppression compared to other M2 subtypes [2]. The observed decrease in these subsets relative to M2B further supports a shift towards an immunosuppressive and pro-tumorigenic macrophage phenotype in colon cancer.
• Implications for Tumor Microenvironment: This imbalance, particularly the skewing towards M2B, suggests that macrophages in the colon tumor microenvironment are largely adopting functions that favor tumor growth, angiogenesis, and immune evasion rather than anti-tumor immunity. This is a common phenomenon in many solid tumors, where tumor-associated macrophages (TAMs) are often polarized towards M2-like phenotypes.

Clinical or Translational Implications

The pronounced shift towards M2B macrophage polarization in colon tumors has several clinical implications:

• Prognostic Marker: A high proportion of M2B macrophages in the tumor could potentially serve as a prognostic marker for worse outcomes in colorectal cancer patients, given their established roles in promoting tumor progression and immune suppression.
• Therapeutic Target: Targeting M2B macrophages or pathways involved in their polarization could represent a promising therapeutic strategy. Re-educating TAMs from an M2-like (specifically M2B) to an M1-like phenotype could enhance anti-tumor immunity and improve the efficacy of existing treatments like immunotherapy [3].
• Biomarker for Response to Therapy: Monitoring the polarization state of macrophages, particularly the M1/M2B ratio, could potentially serve as a biomarker to predict response to certain immunotherapies or to evaluate the effectiveness of macrophage-targeting agents.

---

References:

[1] Qian, B. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. *Cell*, 141(1), 39-51. PubMed Search: Macrophage diversity tumor progression

[2] Sica, A., & Mantovani, A. (2012). Macrophage plasticity and polarization: in vivo insights. *Immunity*, 37(6), 1034-1042. PubMed Search: Macrophage plasticity polarization in vivo

[3] Pathria, P., Louis, T. L., & Caputo, S. (2019). The tumor microenvironment at a glance: The macrophage. *Journal of Cell Science*, 132(11), jcs229941. PubMed Search: Tumor microenvironment macrophage therapy

8. Differential T cell Subset Populations in Colon Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional differences of various T cell and Innate Lymphoid Cell (ILC) subsets between colon tumor tissue and adjacent normal tissue. The box plots visualize these proportions, with statistical significance indicated by p-values, highlighting shifts in the immune landscape associated with the tumor microenvironment.

Visual Summary

The visualization presents box plots for eight distinct T cell and ILC subsets, comparing their proportions in 'Tumor' (blue boxes) versus 'Adj_normal' (orange boxes) conditions. Statistically significant differences (p-value < 0.1) are observed for several subsets:

• Treg: Significantly increased in Tumor tissue (median proportion ~12%) compared to Adjacent Normal tissue (median proportion ~3%) (p ≤ 1e-5).
• ILC1: Significantly decreased in Tumor tissue (median proportion ~1.5%) compared to Adjacent Normal tissue (median proportion ~5.5%) (p ≤ 0.001).
• LTI (Lymphoid Tissue Inducer cells): Significantly decreased in Tumor tissue (median proportion ~2.5%) compared to Adjacent Normal tissue (median proportion ~10.5%) (p ≤ 0.001).
• T_Cyto (Cytotoxic T cells): Significantly decreased in Tumor tissue (median proportion ~45%) compared to Adjacent Normal tissue (median proportion ~50%) (p ≤ 0.05).
• Tfh (T follicular helper cells): Significantly increased in Tumor tissue (median proportion ~15%) compared to Adjacent Normal tissue (median proportion ~9.5%) (p ≤ 0.01).
• Th17: Significantly increased in Tumor tissue (median proportion ~6.5%) compared to Adjacent Normal tissue (median proportion ~3.5%) (p ≤ 1e-4).
• NK (Natural Killer cells): Shows a trend of increased proportion in Tumor tissue (median proportion ~0.3%) compared to Adjacent Normal tissue (median proportion ~0.2%), with borderline significance (p = 0.08).
• ILC2: Shows a trend of decreased proportion in Tumor tissue (median proportion ~0.15%) compared to Adjacent Normal tissue (median proportion ~0.35%), with borderline significance (p = 0.08).

Biological Interpretation

The observed shifts in T cell and ILC subset populations in colon tumor tissue suggest a highly altered and potentially immunosuppressive or pro-tumorigenic immune microenvironment:

• Immune Suppression: The most striking finding is the significant increase in Treg cells (Regulatory T cells) and a decrease in T_Cyto cells (Cytotoxic T cells) within the tumor. Tregs are known for their potent immunosuppressive functions, actively suppressing anti-tumor immune responses by effector T cells like cytotoxic T cells. This imbalance strongly points towards an immunosuppressive tumor microenvironment that favors tumor growth and immune evasion [1].
• Compromised Innate Anti-tumor Immunity: The significant decrease in ILC1s is concerning. ILC1s are critical producers of IFN-gamma, which is essential for mounting effective anti-tumor immune responses and enhancing cellular cytotoxicity [2]. Their reduction suggests a weakened innate immune surveillance. Similarly, the decrease in LTI cells, which are crucial for the development and maintenance of lymphoid tissues and tertiary lymphoid structures, could imply altered immune architecture and potentially impaired immune cell priming within the tumor [3].

Inflammatory and Humoral Immunity Shifts:

• The significant increase in Th17 cells indicates an active inflammatory component within the tumor microenvironment. Th17 cells have a context-dependent role in cancer; in colorectal cancer, they can sometimes promote tumor progression through inflammation and angiogenesis, although they can also have anti-tumor effects [4].
• The significant increase in Tfh cells suggests altered B cell responses or the formation of structures that support humoral immunity within the tumor. Tfh cells are essential for B cell activation and antibody production. Their role in the tumor context can be complex, influencing anti-tumor or pro-tumor antibody responses [5].
• Borderline Changes: While borderline significant, the trend for higher NK cells in the tumor might represent an attempt by the innate immune system to counter the tumor, though their functionality can often be compromised in the TME. The trend for lower ILC2s could suggest a shift away from type 2 immunity, but its precise implications in colon cancer require further investigation.

Clinical or Translational Implications

These findings have important clinical and translational implications for colon cancer:

• Immunosuppressive Microenvironment: The observed landscape, characterized by increased Tregs and decreased cytotoxic T cells and ILC1s, strongly indicates an immunosuppressive tumor microenvironment that can hinder effective anti-cancer immunity.
• Prognostic Biomarkers: The proportions of these T cell and ILC subsets, particularly Tregs, cytotoxic T cells, and ILC1s, could serve as prognostic biomarkers, potentially correlating with disease progression or patient survival in colon cancer.

Therapeutic Targets:

• The enrichment of Tregs highlights them as a potential target for immunotherapeutic strategies aimed at reversing immunosuppression, such as Treg depletion or inhibition of their function.
• The deficit in cytotoxic T cells suggests a need for therapies that enhance their infiltration, activation, or persistence, which is a core mechanism of many current immunotherapies (e.g., checkpoint inhibitors).
• Restoring ILC1 function or promoting their recruitment could be novel therapeutic avenues to bolster innate anti-tumor immunity.
• Treatment Stratification: Understanding these immune cell shifts could help in stratifying patients for specific immunotherapies or combination treatments that can effectively modulate the tumor immune microenvironment.

---

References:

1. Tregs and cancer immunosuppression: PubMed Search: "Treg cancer immunosuppression"
2. ILC1 and cancer immunity: PubMed Search: "ILC1 cancer immunity"
3. LTI cells and tertiary lymphoid structures in cancer: PubMed Search: "LTI cells tumor tertiary lymphoid structures"
4. Th17 in colorectal cancer: PubMed Search: "Th17 colorectal cancer"
5. Tfh cells and B cell immunity in cancer: PubMed Search: "Tfh cells cancer B cell immunity"

9. Differences in Macrophage Subpopulations Between Colon Tumor and Adjacent Normal Tissues

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific Macrophage (Mac) subsets within single-cell RNA-seq data from human colon tissue, comparing Tumor conditions against Adj_normal (adjacent normal tissue). The plot_box_for_celltype_population_with_signif_difference tool was used to identify and visualize statistically significant differences in cell type proportions at the celltype_subset taxonomic level, focusing on selected Macrophage subsets.

Visual Summary

The box plots illustrate the celltype proportion for two distinct Macrophage subsets: Mac (M2B) and Mac (M2A), across the 'Adj_normal' and 'Tumor' conditions.

• Mac (M2B): There is a statistically significant increase (p ≤ 0.01) in the proportion of Mac (M2B) cells in the Tumor condition compared to the Adj_normal tissue. The median proportion of Mac (M2B) is substantially higher in tumors (approximately 40-45%) than in adjacent normal tissue (approximately 20-25%). The individual data points (stripplot) demonstrate a clear upward shift in the tumor group.
• Mac (M2A): Conversely, the proportion of Mac (M2A) cells is significantly decreased (p ≤ 0.01) in the Tumor condition relative to the Adj_normal tissue. The median proportion of Mac (M2A) is much lower in tumors (around 5-10%) compared to adjacent normal tissue (around 30%).

Biological Interpretation

Macrophages are highly plastic immune cells that play critical roles in the tumor microenvironment (TME), often polarizing into different functional phenotypes. The observed shifts in specific macrophage subsets in colon cancer suggest a significant reprogramming of the macrophage compartment that likely contributes to disease progression.

• Increased Mac (M2B) in Tumors: M2B macrophages are a subset of alternatively activated (M2) macrophages, often associated with immune regulation, tissue repair, and pro-tumorigenic functions. Their enrichment in the colon tumor microenvironment is consistent with their known roles in promoting tumor growth, angiogenesis, tissue remodeling, and immune suppression. M2B macrophages can contribute to the creation of an immunosuppressive milieu, for instance, by secreting anti-inflammatory cytokines like IL-10 and pro-angiogenic factors, thereby favoring tumor survival and metastasis. This observation aligns with the general understanding of Tumor-Associated Macrophages (TAMs) often adopting an M2-like phenotype in many cancers, including colorectal cancer. GeneCards: IL10, PubMed Search: M2B macrophages cancer
• Decreased Mac (M2A) in Tumors: M2A macrophages are typically induced by Th2 cytokines such as IL-4 and IL-13 and are involved in allergic responses, parasitic infections, and early stages of wound healing. While also an M2 subtype, their reduced proportion in the tumor microenvironment compared to adjacent normal tissue suggests a selective polarization or recruitment of other M2 subsets (like M2B) or a diminished role for the M2A phenotype in established colon tumors. It's possible that the tumor microenvironment in the colon specifically drives a shift away from M2A towards other more advantageous M2-like states, such as M2B, which might be more effective at promoting tumor growth and immune evasion in this specific context.

Overall, these findings highlight a significant shift in the macrophage landscape within colon tumors, favoring pro-tumorigenic M2B cells while reducing M2A populations. This re-polarization likely contributes to the immunosuppressive TME characteristic of many cancers.

Clinical or Translational Implications

The distinct changes in Macrophage subset proportions, particularly the significant increase in M2B macrophages within colon tumors, have several clinical and translational implications:

• Biomarker Potential: The elevated proportion of M2B macrophages could serve as a prognostic biomarker for colon cancer progression, potentially indicating a more aggressive disease phenotype or poor response to certain therapies.
• Therapeutic Targeting: Targeting M2B macrophages or their specific polarization pathways represents a potential therapeutic strategy. Modulating the TME by inhibiting the recruitment, survival, or pro-tumorigenic functions of M2B cells could enhance anti-tumor immunity and improve the efficacy of existing treatments, such as immunotherapies. PubMed Search: Macrophage polarization cancer therapy
• Understanding Disease Mechanisms: These findings deepen our understanding of immune cell dynamics in colon cancer, highlighting the precise shifts within the macrophage compartment that drive tumor progression and immune evasion. Further research into the specific molecular cues driving M2B polarization in the colon TME could reveal novel targets for therapeutic intervention.

The observed changes in macrophage subsets underscore the complexity and plasticity of immune responses in cancer, emphasizing the need for a nuanced approach to immunomodulation in oncology.

10. Ploidy Population Analysis of Tumor-Origin and Unassigned Cells in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of cells identified as "Intestinal Epithelial cell" (designated as the tumor origin cell type) and "unassigned" cells. The ploidy inference, derived from single-cell RNA-seq data, is presented as population percentages per sample, comparing adjacent normal tissue (Adj_normal) with tumor tissue (Tumor) from colon samples. The goal is to highlight differences in genomic stability between these conditions and within specific cell populations.

Visual Summary

The bar plot effectively illustrates the ploidy distribution across individual samples, segregated by condition.

• Adjacent Normal Samples (Adj_normal): All adjacent normal samples (e.g., SMC08-N, SMC05-N) show a remarkably consistent pattern, with nearly 100% of the filtered cells (Intestinal Epithelial cell and unassigned) classified as Diploid (light orange). There is virtually no detectable Aneuploid or Unclear population.
• Tumor Samples (Tumor): In stark contrast, tumor samples display significant heterogeneity in ploidy.
• Many tumor samples (e.g., SMC21-T, SMC16-T, SMC20-T, SMC02-T, SMC09-T, SMC04-T, SMC11-T, SMC01-T, SMC08-T, SMC15-T, SMC25-T, SMC22-T, SMC17-T, SMC14-T, SMC23-T) show a substantial to dominant proportion of Aneuploid cells (maroon), often exceeding 50% and in some cases reaching over 80-90% of the filtered population.
• Conversely, a subset of tumor samples (e.g., SMC03-T, SMC19-T, SMC10-T, SMC06-T, SMC05-T, SMC24-T) exhibit a predominantly Diploid population, similar to the adjacent normal samples, with minimal or no detectable aneuploidy.
• A small fraction of cells in some tumor samples are categorized as "Unclear" (light green), indicating cases where ploidy status could not be definitively assigned. This "Unclear" fraction is generally minor compared to the Aneuploid and Diploid populations.

Biological Interpretation

The observed ploidy patterns strongly correlate with the disease state, providing critical insights into the genomic landscape of colon cancer.

• Genomic Stability in Normal Tissue: The nearly exclusive diploidy in adjacent normal Intestinal Epithelial cells (and any minor unassigned population) is consistent with healthy tissue, where cells maintain a normal complement of chromosomes. This serves as a clear baseline for comparison.
• Aneuploidy as a Hallmark of Cancer: The significant prevalence of aneuploidy in the "Intestinal Epithelial cell" population within tumor samples is a hallmark of malignancy and genomic instability characteristic of many cancers, including colorectal cancer. PubMed: Genomic Instability and Aneuploidy in Cancer
• Aneuploidy in "Intestinal Epithelial cell" directly implicates these cells as the transformed, malignant population, which aligns with their designation as the "Tumor origin celltype."
• Inter-Tumor Heterogeneity: The wide variation in aneuploidy levels among different tumor samples highlights the substantial genomic heterogeneity observed in human cancers. Some tumors exhibit widespread chromosomal instability (high aneuploidy), while others appear more genomically stable (predominantly diploid). This heterogeneity can have implications for tumor behavior, progression, and response to therapy.
• "Unassigned" Cells and Ploidy: While the plot doesn't separate "Intestinal Epithelial cell" from "unassigned" cells in the ploidy distribution, any significant aneuploidy observed in the combined filtered population within tumor samples further corroborates the malignant nature of the cells present. If "unassigned" cells show aneuploidy, it could suggest they are also malignant cells that were difficult to classify, or they are a subset of the tumor-origin epithelial cells.
• Diploid Populations in Tumor: The presence of a substantial diploid cell population even within tumor samples could represent several scenarios:
• Tumor microenvironment: Infiltration by normal diploid stromal or immune cells.
• Early-stage or less aggressive tumor cells: Some tumors or specific clones within a tumor might initially be diploid or have more localized genomic alterations not captured as broad aneuploidy.
• Contamination or benign cells: Normal epithelial cells from benign glands within the tumor biopsy.

Clinical or Translational Implications

• Diagnostic and Prognostic Value: Ploidy status, particularly aneuploidy, has long been recognized as a prognostic factor in various cancers. High levels of aneuploidy can be associated with more aggressive tumor phenotypes, poorer prognosis, and higher metastatic potential in colorectal cancer. PubMed: Ploidy and prognosis colorectal cancer
• Therapeutic Stratification: Understanding the genomic stability, or lack thereof, of a patient's tumor could inform treatment strategies. Tumors with high aneuploidy might respond differently to chemotherapy agents or targeted therapies that exploit genomic vulnerabilities.
• Targeting Genomic Instability: The pathways leading to aneuploidy are potential therapeutic targets. For instance, therapies targeting mitotic checkpoints or DNA repair mechanisms might be more effective in highly aneuploid tumors.
• Quality Control for Single-cell CNV Inference: The "Unclear" category, though small here, serves as a useful indicator of data quality or the limits of ploidy inference. In cases with a large "Unclear" fraction, caution might be warranted in interpreting CNV data for those samples.

11. Colon Tumor Microenvironment: Cell-Cell Interaction Patterns

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns within the colon tumor microenvironment (TME) focusing on key cell populations: tumor-origin Intestinal Epithelial cells (distinguished by ploidy as Diploid or Aneuploid), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+). Using CellPhoneDB, ligand-receptor interactions were identified and visualized, highlighting up to 80 significant interactions in the 'Tumor' condition. The goal is to identify critical communication axes that may drive tumor progression, immune evasion, or TME remodeling.

Visual Summary

The dot plot visualizes the strength (color, log2(mean)) and significance (size, -log10(p-value)) of predicted ligand-receptor interactions between specified cell pairs in the tumor condition.

• Aneuploid Intestinal Epithelial Cells as Central Hubs: Aneuploid Intestinal Epithelial cells, representing the likely tumor cell population, demonstrate numerous and highly significant interactions. They exhibit strong self-interactions, particularly through the SPP1-integrin_aVb1_complex and other integrin-mediated adhesion molecules (e.g., integrin_aVb3_complex, integrin_aVb1_complex self-interactions), as well as CD58-CD2 and ALCAM-CD6.
• Differential Interactions by Ploidy: Compared to Diploid Intestinal Epithelial cells, Aneuploid Intestinal Epithelial cells show a more intense and broader spectrum of interactions. For example, the SPP1-integrin self-interaction is notably stronger and more significant in Aneuploid cells. Aneuploid cells also display strong interactions with Macrophages via SPP1-CD44 and with both T CD4+ and T CD8+ cells via adhesion molecules like CD58-CD2 and ALCAM-CD6, as well as potential immune suppressive interactions like HLA-F-LILRB1 with T CD8+ cells.
• Macrophage-Mediated Interactions: Macrophages are highly interactive cells within the TME. They show robust self-interactions via the SPP1-CD44 axis, as well as chemokine signaling (e.g., CCL3-CCR1/CCR5, CCL4-CCR1/CCR5). Macrophages also interact strongly with both Diploid and Aneuploid Intestinal Epithelial cells, notably through the SPP1-CD44 pair.
• T Cell Engagement: T CD4+ and T CD8+ cells engage in significant interactions with Intestinal Epithelial cells (both diploid and aneuploid), primarily through adhesion molecules such as CD58-CD2 and ALCAM-CD6. The HLA-F-LILRB1 interaction between Aneuploid Intestinal Epithelial cells and T CD8+ cells is a prominent feature, suggesting an inhibitory pathway.
• Fibroblast Involvement: Fibroblasts participate in interactions with Intestinal Epithelial cells, Macrophages, and other Fibroblasts. Notable interactions include APP-TNFRSF21 with Aneuploid Intestinal Epithelial cells and Macrophages, and THBS1-CD36 within Fibroblast self-interactions.

Biological Interpretation

The observed cell-cell interaction patterns provide critical insights into the biological mechanisms at play in the colon tumor microenvironment.

• Aneuploidy Drives Pro-Tumorigenic Signaling: The heightened and distinct interaction profile of Aneuploid Intestinal Epithelial cells strongly suggests that genomic instability directly contributes to an altered intercellular communication landscape. The robust SPP1-integrin self-interactions indicate increased cell adhesion, motility, and survival cues within the tumor cell population. SPP1 (Osteopontin) is a well-known secreted phosphoprotein involved in extracellular matrix remodeling, cell migration, and immune modulation, often upregulated in cancer and associated with aggressive phenotypes. GeneCards SPP1
• SPP1-CD44 Axis in Immune Evasion and Tumor Progression: The prominent interactions between Aneuploid Intestinal Epithelial cells and Macrophages (and within Macrophages) via SPP1-CD44 axis are highly significant. This axis is critical for promoting cancer cell survival, invasion, metastasis, and orchestrating an immunosuppressive microenvironment by polarizing macrophages towards a pro-tumorigenic (M2-like) phenotype. Macrophages, in turn, can produce SPP1, further amplifying this pro-tumorigenic loop. PubMed search: SPP1 CD44 tumor macrophage
• Immune Checkpoints and Adhesion Molecules Dictate T Cell Fate: Interactions involving T cells, such as CD58-CD2 and ALCAM-CD6, highlight the importance of adhesion and co-stimulatory pathways in T cell recruitment and activation within the TME. However, the strong interaction of HLA-F-LILRB1 between Aneuploid Intestinal Epithelial cells and T CD8+ cells is particularly notable. LILRB1 (Leukocyte Immunoglobulin Like Receptor B1) is an inhibitory receptor on immune cells. Its engagement by HLA-F on tumor cells can suppress T cell function, contributing to immune evasion, a critical mechanism for tumor survival. GeneCards LILRB1
• Fibroblast Contributions to TME Remodeling: Fibroblasts, key stromal components, show interactions such as THBS1-CD36 and APP-TNFRSF21. THBS1 (Thrombospondin 1) is a matricellular protein that can regulate angiogenesis and immune cell function. These interactions suggest their role in shaping the extracellular matrix, influencing angiogenesis, and modulating immune responses within the tumor.

Clinical or Translational Implications

The identified cell-cell interaction patterns offer several potential avenues for clinical and translational applications in colon cancer.

Therapeutic Target Prioritization:

• SPP1-CD44 axis: Given its strong involvement in interactions between Aneuploid Intestinal Epithelial cells and Macrophages, and its known role in immune evasion and tumor progression, targeting SPP1 or CD44 could disrupt critical pro-tumorigenic crosstalk. Antibodies or small molecules designed to block this interaction could be explored as potential therapies.
• HLA-F-LILRB1 pathway: The interaction between Aneuploid Intestinal Epithelial cells and T CD8+ cells via HLA-F-LILRB1 represents a potential immune checkpoint. Blocking LILRB1 or HLA-F could release the brakes on anti-tumor T cell responses, thereby enhancing immunotherapy efficacy. This is akin to targeting PD-1/PD-L1.
• Integrin complexes: The prominent role of various integrins in tumor cell self-adhesion and interactions with other TME components suggests integrin inhibitors, already explored in some cancers, could be relevant in colon cancer to reduce invasion and metastasis. PubMed search: Integrin inhibitors cancer
• Biomarker Discovery: The expression levels of genes involved in these key interactions (e.g., SPP1, CD44, HLA-F, LILRB1, ALCAM, CD6, CD58, CD2) could serve as prognostic biomarkers for disease aggressiveness or predictors of response to specific targeted therapies.
• Experimental Validation Strategies: The identified ligand-receptor pairs provide a strong foundation for focused experimental validation. In vitro co-culture experiments using patient-derived organoids (Aneuploid Intestinal Epi) and immune cells (Macrophages, T cells) could confirm the functional consequences of these interactions. In vivo studies using genetic knockouts or neutralizing antibodies in preclinical models could further evaluate their therapeutic potential. For instance, investigating the impact of SPP1 or LILRB1 blockade on T cell activation, macrophage polarization, and tumor growth would be crucial.

12. Cell-Cell Interaction Analysis in Colon Tissue: Normal vs. Tumor Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCIs) in human colon tissue under both adjacent normal (Adj_normal) and tumor (Tumor) conditions using single-cell RNA sequencing data. CellPhoneDB was utilized to infer ligand-receptor interactions, and the results are visualized as dot plots, showing the strength (mean expression) and significance (-log10(p-value)) of interactions between various cell type pairs and ligand-receptor complexes. The analysis specifically highlights up to 80 most significant interactions for each condition, providing a comparative view of the intercellular communication landscape. The cell types on the Y-axis are detailed, often incorporating ploidy status (Diploid, Aneuploid) to distinguish potentially malignant epithelial cells from normal ones, especially for the Intestinal Epithelial cell lineage which is the specified tumor origin cell type.

Visual Summary

Adjacent Normal (Adj_normal)

• Overall Interaction Pattern: The Adj_normal plot shows a diverse range of cell-cell interactions, though generally less dense and with lower overall mean expression values compared to the tumor condition.
• Key Interacting Cell Types: Interactions are observed among various immune cells (T cells, B cells, Plasma cells, ILCs), stromal cells (Fibroblasts, Endothelial cells), and Diploid Intestinal Epithelial cells.
• Prominent Ligand-Receptor Pairs: Several integrin-related interactions (e.g., COL1A1_integrin, COL3A1_integrin, FN1_integrin) are visible, suggesting active extracellular matrix (ECM) remodeling and cell adhesion processes. Immune interactions like CD86-CD28, HLA_DRB1-CD4, and ICAM1 related pairs are also present, indicative of normal immune surveillance and antigen presentation. Prostaglandine2_by_PTGES3-PTGER4 suggests prostaglandin-mediated signaling, potentially involved in local inflammation or tissue repair.

Tumor

• Overall Interaction Pattern: The Tumor plot displays a markedly higher density and generally stronger (larger dot size, indicating higher mean expression) and more significant (brighter yellow color, indicating higher -log10(p)) cell-cell interactions compared to Adj_normal. This suggests a highly active and complex communication network within the tumor microenvironment (TME).
• Emergence of Aneuploid Epithelial Cells: Aneuploid Intestinal Epithelial cells (likely the cancerous cells) are heavily involved in a wide array of interactions, often as partners in prominent ligand-receptor pairs.

Key Interacting Cell Types and Ligand-Receptor Pairs:

• Immune Checkpoints/Modulation: The interaction CD274-CD80 (PD-L1-CD80) is notably prominent, particularly between Mac/Aneuploid Intestinal Epi cells, highlighting potential immune evasion mechanisms within the TME. HLA-DR/DQ/DP interactions with T cells are also present, suggesting antigen presentation, although its context within the TME requires further investigation.
• ECM Remodeling and Adhesion: A strong signature of SPP1_integrin_avB1_complex, SPP1_integrin_avB5_complex, SPP1_integrin_avB6_complex, and SPP1_integrin_avB3_complex is observed, involving Mac/Aneuploid Intestinal Epi cells. This indicates significant involvement of secreted phosphoprotein 1 (SPP1), also known as osteopontin, in mediating cell adhesion, migration, and ECM interactions, often crucial for tumor progression and metastasis.
• Growth Factor Signaling: Interactions involving HBEGF_EGFR and EGF_EGFR are visible, particularly between Mac and Aneuploid Intestinal Epithelial cells. These are well-known pathways promoting cell proliferation and survival in cancer.
• Immune Cell Interactions: APOE_TREM2 interactions are seen involving Mac cells, suggesting altered macrophage function within the TME. ICAM1 interactions with T cells persist, likely involved in immune cell trafficking or potentially T-cell exhaustion.
• Angiogenesis/Stromal Interactions: VEGFA-VEGFR2 (not explicitly shown in the top 80, but generally relevant to tumor angiogenesis) and various fibroblast-endothelial interactions are expected in the broader CCI landscape of tumor.

Biological Interpretation

The differential cell-cell interaction patterns between Adj_normal and Tumor conditions provide critical insights into the pathophysiology of colorectal cancer.

1. Shift to Pro-tumorigenic Signaling: The Tumor microenvironment shows a dramatic increase in the number, strength, and significance of cell-cell interactions. This reflects the dynamic and complex cross-talk necessary for tumor growth, immune evasion, angiogenesis, and metastasis. The prominence of interactions involving Aneuploid Intestinal Epithelial cells underscores their central role in orchestrating the TME.
2. Immune Evasion Mechanisms: The strong CD274-CD80 (PD-L1-CD80) interaction in Tumor, particularly involving Macrophages and Aneuploid Intestinal Epithelial cells, suggests a potential mechanism for immune escape. PD-L1 (CD274) expressed by tumor cells and macrophages can bind to CD80 on T cells, leading to T-cell anergy or exhaustion, thereby blunting anti-tumor immune responses.

• Reference: PubMed search for "PD-L1 CD80 immune evasion cancer"

3. ECM Remodeling and Metastasis: The enhanced interactions involving SPP1 with various integrin_avB_complexes are highly significant. SPP1, or osteopontin, is a secreted glycoprotein that plays a crucial role in cell adhesion, migration, and survival through its interaction with integrins, particularly in cancer progression, metastasis, and angiogenesis. The prominent involvement of Macrophages and Aneuploid Intestinal Epithelial cells in these interactions suggests that these cell types are actively modifying the ECM to facilitate tumor invasion and spread.

• Reference: GeneCards entry for SPP1
• Reference: UniProt entry for SPP1 (OPO)

4. Growth and Survival Pathways: The strong HBEGF_EGFR and EGF_EGFR interactions point to activated epidermal growth factor receptor (EGFR) signaling in the Tumor microenvironment. EGFR signaling is a well-established driver of proliferation, survival, and differentiation in various cancers, including colorectal cancer. The involvement of Macrophages in these interactions suggests they might secrete these growth factors, further promoting tumor growth.

• Reference: PubMed search for "EGFR signaling colorectal cancer"

5. Macrophage Reprogramming: The presence of APOE_TREM2 interactions, along with the extensive involvement of Macrophages in pro-tumorigenic signaling (e.g., SPP1-integrin, CD274-CD80, EGF-EGFR), indicates a reprogramming of macrophages towards a tumor-associated macrophage (TAM) phenotype. TAMs are known to promote tumor growth, angiogenesis, and immune suppression.

• Reference: PubMed search for "TREM2 tumor associated macrophage"

Clinical or Translational Implications

The identified cell-cell interactions offer compelling targets for therapeutic intervention and opportunities for biomarker discovery in colorectal cancer.

1. Immunotherapy Targets: The prominent CD274-CD80 interaction (PD-L1-CD80) reinforces the rationale for targeting the PD-1/PD-L1 axis in colorectal cancer, especially in patient subsets where this interaction is highly active. Given that PD-L1 is expressed by both tumor cells and macrophages, combination therapies targeting multiple immune checkpoints or modulating TAM function could be explored.
2. Targeting SPP1-Integrin Axis: The pervasive SPP1-integrin interactions present a strong candidate for therapeutic targeting. Inhibitors of SPP1 or specific integrin receptors (e.g., integrin alpha-v beta-3, beta-5, beta-6) could disrupt tumor cell adhesion, migration, and metastasis, potentially enhancing the efficacy of conventional therapies. This axis could also serve as a prognostic biomarker for metastatic potential.
3. EGFR Inhibition Strategies: The activation of EGFR signaling via HBEGF and EGF in the TME confirms EGFR as a critical driver. For patients where this pathway is highly active, EGFR inhibitors (e.g., cetuximab, panitumumab) could be effective. The involvement of macrophages in providing ligands suggests that combination strategies targeting both tumor cells and the supportive TME could be beneficial.
4. Macrophage-Targeted Therapies: The observed involvement of macrophages in multiple pro-tumorigenic interactions (SPP1, PD-L1, EGF/HBEGF, APOE-TREM2) highlights macrophages as a key therapeutic target. Strategies to deplete TAMs, reprogram them to an anti-tumor phenotype, or inhibit their pro-tumorigenic signaling could be explored.
5. Biomarker Discovery and Validation: The identified ligand-receptor pairs and the cells involved could serve as novel biomarkers for disease progression, response to therapy, or prognosis. For example, high expression of SPP1 or PD-L1 on tumor cells or TAMs, or specific integrin expression patterns, could predict patient outcomes or guide treatment selection. Experimental validation through immunohistochemistry (IHC) or multi-spectral imaging to confirm protein expression and co-localization of these ligand-receptor pairs in tissue sections would be a crucial next step. In vitro co-culture experiments mimicking the identified cell-cell interactions could further elucidate the functional consequences of these communications.

13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) mediated by a curated set of immune checkpoint and cell cycle-related genes within colon tissue. CellPhoneDB was used to identify significant ligand-receptor interactions across different cell types and conditions (Adj_normal vs. Tumor). The results are visualized as dot plots, where dot size represents the significance of the interaction (p-value) and color indicates the mean expression level of the ligand-receptor pair.

Visual Summary

1. Cell-Cell Interactions in Adj_normal Condition:

• The "Adj_normal" plot shows a relatively sparse pattern of significant interactions.
• Key interactions observed involve B cells, ILCs (Innated Lymphoid Cells), and T cells (CD4+ and CD8+).
• Specifically, ICOSLG-ICOS interactions are seen between B cells and T cell CD4+, and between B cells and ILCs.
• A PVR-TIGIT interaction is identified between B cells and T cell CD8+.
• The mean expression levels (log2(m)) for these interactions range from approximately 0.4 to 0.8, and the p-values (-log10(p)) are moderately significant (mostly around 2-5).

2. Cell-Cell Interactions in Tumor Condition:

• In stark contrast, the "Tumor" plot displays a much broader and more intense landscape of cell-cell interactions.
• A prominent feature is the involvement of Macrophages and both Diploid and Aneuploid Intestinal Epithelial cells interacting with T cells (CD4+ and CD8+).

Several critical immune checkpoint pathways are active

• CD80-CD28 and CD86-CD28 interactions: Predominantly seen between Macrophages and T cells (CD8+, CD4+), and extensively between both Diploid and Aneuploid Intestinal Epithelial cells and T cells (CD8+, CD4+).
• CD86-CTLA4 interactions: Also widely observed between Macrophages and T cells, and between Diploid/Aneuploid Intestinal Epithelial cells and T cells.
• LGALS9-HAVCR2 (Galectin-9-TIM-3) interactions: Present between Macrophages and T cells (CD8+, CD4+), and Diploid/Aneuploid Intestinal Epithelial cells and T cells (CD8+, CD4+).
• PVR-TIGIT interactions: Strongest between Diploid/Aneuploid Intestinal Epithelial cells and T cells (CD8+, CD4+), and also present involving Macrophages.
• Compared to "Adj_normal," the interactions in the "Tumor" condition generally exhibit higher mean expression values (up to 1.0) and significantly lower p-values (up to -log10(p) ~10), indicating stronger and more robust interactions.
• Notably, none of the cell cycle related genes (CCND1, CDK4, CDKN2A, TP53, MKI67, AURKA, BUB1, CDC20) specified in the analysis were found to mediate significant cell-cell interactions above the applied cutoffs in either condition. This suggests that these genes, while critical for cell cycle regulation, do not primarily function as direct cell-surface ligands or receptors in the observed CCI.

Biological Interpretation

The dramatic shift in cell-cell interaction patterns from "Adj_normal" to "Tumor" colon tissue, particularly concerning immune checkpoint molecules, provides critical insights into the tumor microenvironment (TME).

1. Immune Activation and Suppression in Normal Tissue: In the adjacent normal tissue, the observed ICOSLG-ICOS and PVR-TIGIT interactions involving B cells, ILCs, and T cells suggest a basal level of immune regulation. ICOS-ICOSLG signaling is generally considered a co-stimulatory pathway for T cells [1], while TIGIT is an inhibitory receptor [2]. This balance likely contributes to immune homeostasis and surveillance in healthy colon tissue.
2. Extensive Immune Evasion and T-cell Modulation in Tumor Microenvironment: The "Tumor" condition reveals a highly complex and active immune landscape.

• Macrophage-T cell Interactions: Macrophages, known as key regulators in the TME, extensively interact with both CD4+ and CD8+ T cells via both co-stimulatory (CD80/CD86-CD28) and inhibitory (CD86-CTLA4, LGALS9-HAVCR2, PVR-TIGIT) pathways. This suggests that tumor-associated macrophages (TAMs) are actively shaping T cell responses, likely promoting an immunosuppressive environment that benefits tumor growth.
• Tumor Cell-T cell Interactions via Immune Checkpoints: The most striking observation is the direct and widespread interaction between Intestinal Epithelial cells (both Diploid and Aneuploid) and T cells using the same immune checkpoint molecules.
• The presence of CD80/CD86-CD28 interactions on epithelial cells might indicate an attempt by tumor cells to present antigens or engage T cells. However, simultaneously high levels of CD86-CTLA4, LGALS9-HAVCR2, and PVR-TIGIT interactions strongly point towards tumor-mediated immune evasion.
• CTLA4 (Cytotoxic T-lymphocyte-associated protein 4) outcompetes CD28 for CD80/CD86, leading to T cell anergy or inactivation [3].
• TIM-3 (T-cell immunoglobulin and mucin-domain containing-3, ligand LGALS9/Galectin-9) and TIGIT (T cell immunoreceptor with Ig and ITIM domains, ligand PVR/CD155) are well-established inhibitory checkpoints that promote T cell exhaustion, particularly in chronic inflammation and cancer [4, 5].
• Ploidy and Tumor Evolution: The distinction between Diploid and Aneuploid Intestinal Epithelial cells is crucial. Aneuploidy is a hallmark of cancer and often associated with more aggressive tumors. The observation that *both* Diploid and Aneuploid epithelial cells engage in these extensive immune checkpoint interactions with T cells suggests that immune evasion mechanisms are present early in tumor development (diploid cells that may be pre-malignant or early transformed) and become highly pronounced in established malignant (aneuploid) cells. This indicates a broad adaptation by the tumor to suppress anti-tumor immunity.

3. Absence of Cell Cycle Gene-mediated CCI: The lack of significant cell-cell interactions mediated by the selected cell cycle genes confirms their primary intracellular role in regulating cell division rather than serving as direct ligand-receptor pairs for intercellular communication in this context.

Clinical or Translational Implications

The profound and distinct patterns of immune checkpoint interactions in the tumor microenvironment offer several important clinical and translational implications for colon cancer.

1. Therapeutic Target Prioritization: The prominence of CTLA4, TIM-3 (HAVCR2), and TIGIT interactions involving both tumor cells (Intestinal Epithelial cells) and various immune cells (Macrophages, T cells) strongly suggests these pathways as potential therapeutic targets.

• CTLA-4: Given the CD86-CTLA4 interaction, therapies blocking CTLA-4 (e.g., ipilimumab) could be considered, potentially reversing T cell suppression.
• TIM-3 (HAVCR2) and TIGIT: The robust LGALS9-HAVCR2 and PVR-TIGIT interactions highlight TIM-3 and TIGIT as promising targets, possibly in combination with PD-1/PD-L1 blockade or other immunotherapies, to counteract T cell exhaustion and enhance anti-tumor immunity. [6, 7]
• CD28 agonism: While less common for direct targeting, understanding the CD80/CD86-CD28 interactions in the TME can inform strategies to boost co-stimulation, perhaps through combination therapies.

2. Biomarker Identification: The specific cell-cell interaction patterns could serve as biomarkers to predict response to immune checkpoint inhibitors. For instance, high expression or significant interactions involving PVR-TIGIT or LGALS9-HAVCR2 might identify patients who would benefit from anti-TIGIT or anti-TIM-3 therapies.
3. Understanding Resistance Mechanisms: The co-occurrence of multiple inhibitory interactions (e.g., CTLA-4, TIM-3, TIGIT) in the same tumor microenvironment suggests redundant or synergistic mechanisms of immune evasion. This provides a rationale for investigating combination immunotherapies that target multiple inhibitory pathways simultaneously to overcome resistance to single-agent therapies.
4. Novel Insights into Tumor Biology: The finding that even "Diploid Intestinal Epithelial cells" in the tumor context participate in extensive immune checkpoint interactions suggests that immune evasion mechanisms might be engaged even in early or pre-malignant stages. This could open avenues for early intervention strategies or for understanding how the tumor microenvironment facilitates the progression of diploid to aneuploid (fully malignant) cells.
5. Experimental Validation: These findings warrant experimental validation, such as:

• *In vitro* co-culture experiments using patient-derived colon epithelial cells (diploid and aneuploid subsets) and T cells to confirm the functional consequences of observed ligand-receptor interactions.
• Immunohistochemistry or spatial transcriptomics on colon cancer tissues to localize and quantify these specific ligand and receptor expressions on interacting cell populations.
• Functional assays to assess T cell activation, proliferation, and cytokine production in the presence of these interacting partners, with and without blocking antibodies against the identified immune checkpoints.

These results underscore the complexity of tumor-immune interactions in colon cancer and provide a data-driven basis for prioritizing therapeutic targets and designing more effective immunotherapy strategies.

---

References:

[1] ICOS-ICOSLG signaling: PubMed search for "ICOS ICOS ligand T cell co-stimulation"

[2] TIGIT: GeneCards TIGIT

[3] CTLA4 mechanism: PubMed search for "CTLA4 T cell inhibition"

[4] TIM-3 (HAVCR2): GeneCards HAVCR2

[5] PVR-TIGIT axis: PubMed search for "PVR TIGIT immune checkpoint"

[6] Anti-TIGIT in cancer: PubMed search for "anti-TIGIT cancer therapy"

[7] Anti-TIM-3 in cancer: PubMed search for "anti-TIM-3 cancer therapy"

14. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates statistically significant differences in cell-cell interactions (CCIs) between 'Adj_normal' (adjacent normal) and 'Tumor' conditions in human colon tissue, focusing on major immune and stromal cell types. The dot plot visualizes the strength (standardized sample mean, color intensity) and statistical significance (-log10(p-value), dot size) of specific ligand-receptor interactions across individual samples within each condition. This approach highlights CCIs that are predominantly active in one condition but diminished or absent in the other, offering insights into condition-specific microenvironmental cues.

Visual Summary

The dot plot clearly segregates CCIs into two distinct patterns based on the tissue condition:

• Adjacent Normal-Specific Interactions (Top-Left Quadrant): A prominent cluster of strong and highly significant CCIs is observed in 'Adj_normal' samples (SMC01-N to SMC10-N). These interactions are largely absent or significantly weaker in 'Tumor' samples. Key interactions in this cluster involve:
• Chemokine Signaling: CXCL14-CXCR4 axis between Fibroblasts (Fib) and T cells (CD4+, CD8+) or B cells. [GeneCards: CXCL14] [GeneCards: CXCR4]
• Lipid Mediator Signaling: Prostaglandin E2 (PGE2) pathway (via PTGES2/3/4) involving Fibroblasts and T cells (CD4+, CD8+) or Intestinal Epithelial cells (Ent.Epi). [GeneCards: PTGES2] [GeneCards: PTGES3] [GeneCards: PTGES4]
• Adhesion Molecules: VCAM1-integrin_a4b1_complex between Intestinal Epithelial cells and Fibroblasts. [GeneCards: VCAM1]
• Cell-Cell Adhesion/Signaling: LPAR1-ADGRE5 and DLL1-NOTCH2 interactions involving Fibroblasts.
• Tumor-Specific Interactions (Bottom-Right Quadrant): Conversely, a distinct set of strong and highly significant CCIs emerges almost exclusively in 'Tumor' samples (SMC01-T to SMC25-T), being largely absent or non-significant in 'Adj_normal' samples. This cluster is overwhelmingly dominated by:
• Extracellular Matrix (ECM) Remodeling: Numerous interactions involving various Collagen types (COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, COL6A1, COL6A3, COL12A1) with integrin_a1b1_complex, predominantly between Fibroblasts (Fib-Fib), and also involving T cells (e.g., Fib-T CD8+, Fib-T CD4+). [PubMed: Collagen Integrin Cancer]
• Immune Cell Adhesion: CD58-CD2 interactions between T CD8+ cells. [GeneCards: CD58] [GeneCards: CD2]
• Fibroblast-Immune Interactions: CD55-ADGRE5 between Fibroblasts and T CD4+ cells.
• Condition Specificity: The upper-right and lower-left quadrants of the plot show a general lack of strong, significant interactions, underscoring the condition-specific nature of the highlighted CCIs. This indicates that interactions prominent in normal tissue are suppressed in tumors, and vice-versa for tumor-specific interactions.

Biological Interpretation

The observed shifts in CCI patterns highlight fundamental changes in the cellular microenvironment during colon tumorigenesis:

1. Loss of Homeostatic Immune and Stromal Regulation in Tumors: In adjacent normal tissue, interactions like CXCL14-CXCR4 and PGE2 signaling pathways suggest active communication between fibroblasts, epithelial cells, and various immune cells (T cells, B cells). These interactions are crucial for maintaining tissue homeostasis, immune surveillance, and inflammatory responses. The significant reduction or absence of these pathways in tumor samples implies a disruption of normal tissue regulatory mechanisms, potentially contributing to immune evasion and uncontrolled growth.
2. Profound ECM Remodeling and Desmoplasia in Tumors: The striking prevalence of diverse collagen-integrin interactions in tumor samples points to extensive extracellular matrix (ECM) remodeling, a hallmark of desmoplastic reactions in cancer. Fibroblasts, particularly cancer-associated fibroblasts (CAFs), are key drivers of this process, secreting and reorganizing the ECM. The multitude of collagen types and the consistent engagement of integrin_a1b1_complex suggest a highly complex and altered ECM. This rigid, collagen-rich ECM not only provides structural support for tumor growth and invasion but also creates a physical barrier that can impede immune cell infiltration and function, contributing to an immunosuppressive tumor microenvironment.
3. Altered Immune Cell Interactions in Tumors: The appearance of CD58-CD2 interactions among T CD8+ cells in tumors could reflect specific T cell-T cell communication within the tumor microenvironment, which might be associated with T cell activation, clustering, or potentially exhaustion. Fibroblast-T cell interactions like CD55-ADGRE5 further emphasize the dynamic interplay between stromal and immune cells that shapes tumor progression.

Clinical or Translational Implications

The differential CCI patterns identified between normal and tumor colon tissue provide valuable insights for potential diagnostic and therapeutic strategies:

1. Therapeutic Targeting of the ECM and Integrins: The dominance of collagen-integrin interactions in tumors suggests that targeting the deposition of specific collagen types (e.g., via CAF modulation) or inhibiting critical integrin receptors (e.g., integrin_a1b1_complex) could be a viable therapeutic strategy. This could disrupt tumor cell adhesion, migration, and invasion, potentially enhancing the efficacy of conventional therapies or immunotherapies by altering the tumor microenvironment. [PubMed: Integrin inhibitors cancer]
2. Modulating Immune-Stromal Crosstalk: The observed shifts in chemokine (CXCL14-CXCR4) and lipid mediator (PGE2) signaling highlight opportunities to therapeutically restore immune surveillance. For instance, interventions that re-establish immune-attracting chemokine gradients or modulate PGE2 signaling could reactivate anti-tumor immunity.
3. Biomarker Discovery: The distinct CCI signatures could serve as biomarkers for distinguishing tumor tissue from adjacent normal tissue, or for monitoring disease progression and response to therapy. Further investigation into the specific roles of these key ligand-receptor pairs in larger cohorts could validate their utility as diagnostic or prognostic markers.

15. Intestinal Epithelial Cell의 종양 특이적 표면 마커 분석

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA-seq 데이터를 사용하여 결장 조직의 Intestinal Epithelial cell(장 상피 세포)에서 종양(Tumor) 조건과 인접 정상(Adj_normal) 조건을 비교하여 조건 특이적인 표면(surfaceome) 마커를 식별합니다. 특히, AnnData의 ploidy_dec 정보("Diploid" 대 "Aneuploid")를 활용하여 세포의 이수성(ploidy) 상태를 고려한 마커 발현 패턴을 조사합니다. 이 분석의 목적은 종양 기원 세포(Intestinal Epithelial cell)의 표면에 특이적으로 발현되는 유전자를 식별하여, 잠재적인 진단 바이오마커 또는 치료 표적을 발굴하는 것입니다.

Visual Summary

제공된 닷 플롯은 Intestinal Epithelial cell에서 발현되는 주요 표면 마커 유전자들의 발현 정도와 발현 세포 비율을 시각화합니다.

• Y축: 각 행은 개별 환자 샘플 내의 Intestinal Epithelial cell 군집을 나타내며, 종양(T) 또는 인접 정상(N) 조직 유래인지, 그리고 이수성 상태(Diploid 또는 Aneuploid로 추정되는 비-Diploid)가 명시되어 있습니다. 상단 그룹은 "Diploid SMCxx-T" (이배성 종양), "Diploid SMCxx-N" (이배성 인접 정상) 샘플을 포함하며, 하단 그룹은 "SMCxx-T" (이수성 종양으로 추정) 샘플을 포함합니다.
• X축: 각 열은 분석된 표면 마커 유전자를 나타냅니다.
• 점의 크기: 해당 그룹 내에서 유전자를 발현하는 세포의 비율(Fraction of cells in group)을 나타냅니다. 점이 클수록 더 많은 세포가 해당 유전자를 발현합니다.
• 점의 색상 강도: 해당 그룹 내에서 유전자의 평균 발현량(Mean expression in group)을 나타냅니다. 색상이 짙을수록 평균 발현량이 높습니다.

주요 관찰:

• 이수성 종양 세포에서의 현저한 마커 발현 증가: 하단 그룹의 "SMCxx-T" (이수성 종양으로 추정) 샘플들은 "Diploid SMCxx-N" (이배성 인접 정상) 샘플에 비해 대부분의 표면 마커 유전자에서 높은 발현량과 발현 세포 비율을 보입니다. 이는 이수성을 가진 종양 Intestinal Epithelial cell이 정상 세포와는 확연히 다른 표면 특성을 가짐을 시사합니다.
• 주요 종양 관련 표면 마커의 특징적 발현: CEACAM1, SDC1, EREG, SLC2A1, ITGAE, EFNB1, EFNB2, LY6E, F11R, LAMP2와 같은 유전자들이 "SMCxx-T" 그룹에서 매우 높은 발현 수준과 넓은 발현율을 나타냅니다.
• 이배성 종양 세포에서의 이질성: "Diploid SMCxx-T" 샘플에서는 일부 마커에서 발현 증가가 관찰되지만, "SMCxx-T" 그룹만큼 일관되거나 강렬하지 않으며, 샘플 간 이질성이 더 크게 나타납니다.
• 인접 정상 세포의 낮은 발현: "Diploid SMCxx-N" 샘플은 대부분의 표면 마커에서 매우 낮은 발현을 보이거나 전혀 발현하지 않아, 종양 관련 마커들이 정상 장 상피 세포에서는 거의 나타나지 않음을 확인시켜 줍니다.

Biological Interpretation

이 분석 결과는 결장암의 종양 기원 세포인 Intestinal Epithelial cell이 종양 환경에서 특이적인 표면 마커 발현 변화를 겪음을 명확히 보여줍니다. 특히 이수성 종양 세포(SMCxx-T)는 인접 정상 세포 및 이배성 종양 세포와 비교했을 때, 암 진행 및 특징과 밀접하게 관련된 다수의 표면 단백질을 과발현합니다.

주목할 만한 표면 마커와 그 생물학적 역할은 다음과 같습니다:

• CEACAM1 (Carcinoembryonic Antigen Related Cell Adhesion Molecule 1): 세포 접착 및 면역 조절에 관여하는 당단백질로, 다양한 암종에서 과발현되며 암 진행 및 전이와 관련이 있습니다. 결장암에서도 종양 형성 및 혈관 신생에 중요한 역할을 하는 것으로 알려져 있습니다. GeneCards: CEACAM1
• SDC1 (Syndecan-1): 세포외 기질(ECM) 및 성장 인자와 결합하는 헤파란 황산 프로테오글리칸으로, 세포 증식, 생존, 혈관 신생 및 이동을 촉진하여 암 진행에 기여합니다. GeneCards: SDC1
• EREG (Epiregulin): Epidermal Growth Factor Receptor (EGFR)의 리간드 중 하나로, EGFR 신호 전달 경로를 활성화하여 세포 증식, 이동 및 생존을 촉진합니다. 이는 종양 성장과 치료 저항성에 중요한 역할을 할 수 있습니다. GeneCards: EREG
• SLC2A1 (GLUT1): 포도당 수송체 1로, 암세포의 Warburg 효과(혐기성 해당과정 증가)를 반영하여 포도당 흡수를 증가시켜 빠른 증식을 지원하는 핵심 단백질입니다. GeneCards: SLC2A1
• ITGAE (CD103) 및 ITGB4: 인테그린 서브유닛으로, 세포-ECM 및 세포-세포 상호작용을 매개합니다. 암세포에서는 이들의 발현 조절 이상이 종양 세포의 접착, 이동, 침윤 및 생존에 영향을 미쳐 전이를 촉진할 수 있습니다. GeneCards: ITGAE, GeneCards: ITGB4
• EFNB1/EFNB2 (Ephrin B1/B2): Eph 수용체 티로신 인산화효소의 리간드로, 세포 이동, 접착 및 혈관 신생을 조절하는 Eph/ephrin 신호 전달에 관여합니다. 암에서 이들 신호의 조절 이상은 종양 침윤 및 전이를 촉진하는 것으로 알려져 있습니다. GeneCards: EFNB1, GeneCards: EFNB2
• LY6E (Lymphocyte Antigen 6 Family Member E): GPI-연결 세포 표면 단백질로, 다양한 암종에서 과발현되며 암세포 증식, 생존 및 전이를 촉진하는 데 관여한다고 알려져 있습니다. GeneCards: LY6E
• F11R (JAM-A): Tight junction 형성 및 세포-세포 접착에 관여하는 Junctional Adhesion Molecule A입니다. 암에서 이의 조절 이상은 세포 투과성을 증가시켜 종양 침윤 및 전이를 촉진할 수 있습니다. GeneCards: F11R
• LAMP2 (Lysosomal Associated Membrane Protein 2): 리소좀 기능 및 자가포식(autophagy)에 관여하지만, 세포 표면에도 발현될 수 있으며 암세포의 면역 회피 기전 및 생존에 기여할 수 있습니다. GeneCards: LAMP2

이러한 결과는 이수성 Intestinal Epithelial cell에서 종양 특이적 생물학적 과정이 활성화되어 있음을 시사하며, 이는 종양 미세환경과의 상호작용 또는 세포 고유의 악성 형질 변화를 반영할 수 있습니다.

Clinical or Translational Implications

이수성 종양 Intestinal Epithelial cell에서 고도로 발현되는 표면 마커들은 결장암의 진단 및 치료에 중요한 임상적 의미를 가질 수 있습니다.

• 진단 및 예후 바이오마커: CEACAM1, SDC1, SLC2A1 등은 현재도 암 진단 및 예후 예측에 활용되거나 연구 중인 마커들입니다. 이 분석을 통해 식별된 마커들은 액체 생검(liquid biopsy)을 통한 혈액 내 순환 종양 세포(CTC) 또는 세포외 소포(EV)의 표면 마커로서 종양을 조기에 감지하거나 재발을 모니터링하는 데 활용될 잠재력이 있습니다.
• 치료 표적: 이들 표면 마커는 항체-약물 접합체(ADC), CAR T-세포 치료 또는 기타 표적 치료법 개발을 위한 매력적인 표적 후보가 될 수 있습니다. 종양 세포 표면에 특이적으로 발현되므로, 정상 세포에 대한 독성을 최소화하면서 종양 세포를 효과적으로 표적할 가능성이 있습니다. 예를 들어, EREG은 EGFR 리간드이므로 EGFR 신호 경로를 표적하는 약물 개발의 단서가 될 수 있습니다.
• 약물 저항성 및 전이 연구: EFNB1/EFNB2, ITGAE, ITGB4, F11R 등 세포 접착 및 이동에 관여하는 마커들은 암세포의 전이 과정이나 약물 저항성 기전을 이해하고 이를 극복하기 위한 새로운 치료 전략을 개발하는 데 기여할 수 있습니다.

이러한 표면 마커 후보들의 기능적 검증 및 임상적 유효성 평가는 추가적인 실험(예: 면역조직화학염색, 유세포 분석, 생체 내 실험 모델)을 통해 이루어져야 합니다. 특히 Aneuploid Intestinal Epithelial cell에 집중된 마커 발현 패턴은 종양의 이수성 상태에 따른 치료 반응의 차이를 이해하는 데 중요한 통찰력을 제공할 수 있습니다.

16. Macrophage Condition-Specific Surfaceome Markers in Colon Tumor

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers specifically enriched in Macrophages within the "Tumor" condition of colon tissue, compared to the "Adj_normal" condition (used as a reference for differential expression). The plot_markers_and_expression_dot tool was used to visualize the expression of these markers across different tumor samples. The parameters were configured to identify up to 50 surfaceome markers with specific statistical cutoffs (e.g., log2_FC > 1.5, pval < 0.05) and to display a subset of these markers.

Visual Summary

The dot plot displays the expression patterns of 12 identified surfaceome markers across 20 distinct tumor samples (SMCxx-T) for the Macrophage cell type. Each row represents a tumor sample, and each column represents a specific gene marker.

• Dot Size: The size of each dot corresponds to the fraction of cells within that sample expressing the marker gene. Larger dots indicate a higher percentage of macrophages in that sample expressing the gene.
• Dot Color Intensity: The color intensity (ranging from white to dark red) reflects the mean expression level of the marker gene within the expressing macrophages of that sample. Darker red indicates higher mean expression.
• Sample Cell Count: The bar plot on the right of the dot plot indicates the total number of macrophage cells available in each respective tumor sample, ranging from 40 to 442 cells, confirming sufficient cellular representation for analysis.

Overall, several markers show consistent high expression and prevalence across a majority of the tumor samples. For example, FCGR3A, CD9, OLR1, CCL2, TREM2, and CLEC5A generally appear as larger, darker red dots across many samples, suggesting they are broadly expressed by tumor-associated macrophages. Other genes like ANPEP and CLDN4 show more variable expression or prevalence among the tumor samples. No "Adj_normal" samples are shown, as the plot focuses specifically on the identified condition-specific markers within the tumor context.

Biological Interpretation

The identified surfaceome markers provide insights into the functional state and potential roles of macrophages within the colon tumor microenvironment.

• FCGR3A (CD16a): This Fc-gamma receptor is often expressed on natural killer (NK) cells but also on certain macrophage subsets. Its expression on tumor macrophages can indicate an activated state or a capacity for antibody-dependent cellular cytotoxicity (ADCC), though its role in macrophages in cancer is complex and can be pro- or anti-tumorigenic depending on the context. GeneCards: FCGR3A
• CD9: A tetraspanin protein, CD9 is involved in cell adhesion, migration, and signaling. It is frequently associated with exosomes and can play diverse roles in cancer, including modulating tumor cell invasion and metastasis, as well as immune cell function. Its presence on tumor macrophages may relate to their migratory or intercellular communication functions. GeneCards: CD9
• OLR1 (LOX-1): The oxidized low-density lipoprotein receptor 1 (LOX-1) is a scavenger receptor expressed on various immune cells, including macrophages. It plays roles in inflammation, lipid metabolism, and has been implicated in tumor immunity, potentially contributing to immune suppression or angiogenesis in the tumor microenvironment. GeneCards: OLR1
• CCL2 (MCP-1): This chemokine is a potent recruiter of monocytes and macrophages. Its robust expression by tumor macrophages suggests an autocrine or paracrine mechanism driving further macrophage infiltration and accumulation within the tumor, contributing to the inflammatory and immunosuppressive milieu characteristic of many cancers. GeneCards: CCL2
• TREM2: Triggering receptor expressed on myeloid cells 2 (TREM2) is a crucial surface receptor for macrophage function, involved in phagocytosis, lipid sensing, and survival. In the context of cancer, TREM2-expressing macrophages, often termed tumor-associated macrophages (TAMs), are frequently associated with an immunosuppressive phenotype and support tumor growth, metastasis, and therapy resistance. Its consistent upregulation in tumor macrophages here is a significant finding. GeneCards: TREM2
• CLEC5A: C-type lectin domain family 5 member A is a myeloid cell receptor that recognizes various pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). It plays a role in inflammatory responses and has been linked to pro-inflammatory macrophage polarization, potentially contributing to chronic inflammation in the tumor microenvironment. GeneCards: CLEC5A
• SLC11A1 (NRAMP1), AQP9, MMP14, IL7R, ANPEP, and CLDN4: These genes also show varying levels of expression across tumor samples. SLC11A1 (Natural Resistance-Associated Macrophage Protein 1) is involved in metal ion transport and innate immunity. MMP14 (Matrix Metalloproteinase 14) is a membrane-bound metalloproteinase that degrades extracellular matrix components, critical for tumor invasion and metastasis, suggesting a role for macrophages in tissue remodeling. IL7R (Interleukin-7 Receptor alpha) is known for T cell development but can also be expressed on other immune cells. AQP9 (Aquaporin 9), ANPEP (Aminopeptidase N), and CLDN4 (Claudin-4) are involved in various cellular processes including water transport, peptide metabolism, and tight junction formation, respectively, and their specific roles in tumor macrophages warrant further investigation.

The overall pattern suggests a distinct macrophage phenotype in the colon tumor microenvironment, characterized by markers associated with immune suppression (TREM2), recruitment (CCL2), and tissue remodeling (MMP14, CD9), which collectively contribute to tumor progression.

Clinical or Translational Implications

The identification of these condition-specific surfaceome markers in tumor macrophages offers several clinical and translational avenues:

• Biomarker Discovery: Genes like TREM2, FCGR3A, OLR1, and CCL2 could serve as potential biomarkers for identifying and characterizing tumor-associated macrophages (TAMs) in colon cancer patients. Their expression levels might correlate with disease stage, prognosis, or response to therapy.
• Therapeutic Targets: Several identified surface markers represent potential therapeutic targets.
• Targeting TREM2 has gained significant interest in cancer immunology, with strategies aiming to either inhibit its function to reduce immunosuppression or activate it to promote anti-tumor immunity, depending on the specific context and macrophage subset.
• Blocking CCL2 or its receptor (CCR2) could reduce the recruitment of pro-tumorigenic macrophages to the tumor site.
• Modulating MMP14 activity could impact the ability of macrophages to facilitate tumor invasion and metastasis.
• Immunotherapy Stratification: Understanding the specific surfaceome profile of macrophages could aid in stratifying patients who might benefit from immunotherapies targeting macrophage function or specific macrophage subsets.
• Diagnostic/Prognostic Tool: Developing assays (e.g., flow cytometry, immunohistochemistry) to detect these surface markers on macrophages in patient biopsies could provide valuable diagnostic or prognostic information.

Further experimental validation is crucial to confirm the functional significance of these markers and their utility as therapeutic targets or biomarkers in colon cancer.

17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that are differentially expressed in Fibroblasts depending on their tissue origin: "Adj_normal" (adjacent normal colon tissue) versus "Tumor" (colon tumor tissue). Using single-cell RNA sequencing data, a differential expression analysis was performed, focusing exclusively on genes encoding cell surface proteins. The results are visualized as a dot plot, illustrating both the fraction of cells expressing each marker and the mean expression level within Fibroblast populations from individual samples. This approach helps to pinpoint specific surface molecules that characterize Fibroblasts in the tumor microenvironment compared to those in normal tissue, which can have significant biological and clinical implications.

Visual Summary

The dot plot clearly segregates Fibroblast samples into two main groups based on their gene expression profiles: those from adjacent normal tissue (Adj_normal) and those from tumor tissue (Tumor).

• Adj_normal Specific Markers: A distinct set of genes, including PROCR, PLPP3, SCARA5, ABCA8, ADAM28, CD302, CADM3, CDH11, PTGER4, and ANTXR1, shows high mean expression (dark red color) and high prevalence (large dot size) across most "Adj_normal" samples. These markers are largely absent or expressed at very low levels in "Tumor" samples.
• Tumor Specific Markers: Conversely, a much larger cluster of genes is highly expressed and prevalent in "Tumor" samples, with minimal expression in "Adj_normal" samples. Notable markers in this group include PTTG1IP, PLAUR, PDGFRB, FAP, RPN1, SGCB, SSR1, CD276, PMEPA1, PTK7, PDLIM5, ITGA5, CD82, TMEM30A, TMED7, TM9SF3, ITGB5, ADAM12, NOTCH3, GLIPR1, GJB2, SLC39A14, SLC39A6, CLDN4, NRP2, and SLC52A2. These genes form a robust signature for Fibroblasts found within the tumor microenvironment.
• Clear Segregation: The visualization demonstrates a clear and consistent separation of marker expression patterns between the two conditions across all individual samples, highlighting distinct molecular states of Fibroblasts in normal versus tumor contexts.

Biological Interpretation

The observed condition-specific surfaceome markers indicate significant phenotypic and functional divergence of Fibroblasts in the tumor microenvironment (often referred to as Cancer-Associated Fibroblasts, or CAFs) compared to Fibroblasts in adjacent normal tissue.

• Adj_normal Fibroblasts: Markers such as PROCR (Protein C Receptor, involved in stem cell biology and vascular integrity) and CDH11 (Cadherin-11, important for cell adhesion and migration) might represent a quiescent or homeostatic state of normal tissue-resident Fibroblasts, contributing to tissue maintenance and structure.
• Tumor Fibroblasts (CAFs): The robust upregulation of numerous surface markers in tumor-associated Fibroblasts points towards their activated, pro-tumorigenic phenotype.
• FAP (Fibroblast Activation Protein): A classic and highly reliable marker for CAFs across various solid tumors, including colorectal cancer. FAP is involved in extracellular matrix remodeling, immunosuppression, and promoting tumor growth. GeneCards: FAP
• PDGFRB (Platelet-Derived Growth Factor Receptor Beta): This receptor is crucial for Fibroblast activation, proliferation, and recruitment, and plays a role in angiogenesis within the tumor microenvironment. GeneCards: PDGFRB
• PLAUR (Plasminogen Activator, Urokinase Receptor): Facilitates pericellular proteolysis, cell migration, and tissue invasion, all processes critical for tumor progression and metastasis. GeneCards: PLAUR
• CD276 (B7-H3): An immune checkpoint molecule highly expressed in many cancers and CAFs, contributing to immune evasion and suppression within the tumor microenvironment. GeneCards: CD276
• Integrins (ITGA5, ITGB5): These are key cell-surface receptors that mediate cell-extracellular matrix interactions, crucial for cell adhesion, migration, and signal transduction in the TME. Their upregulation can enhance CAF motility and invasive capabilities. GeneCards: ITGA5
• NRP2 (Neuropilin 2): Involved in various signaling pathways that promote angiogenesis, lymphangiogenesis, and tumor cell survival and metastasis. GeneCards: NRP2
• NOTCH3: Part of the Notch signaling pathway, which is implicated in cell proliferation, survival, and differentiation in cancer, contributing to CAF activation. GeneCards: NOTCH3
• Other markers like PTTG1IP, RPN1, PMEPA1, PTK7, ADAM12, CLDN4 (Claudin-4), and various SLC (Solute Carrier) family members also point to altered metabolic and structural functions of CAFs that support tumor growth and invasion.

Clinical or Translational Implications

The identification of these condition-specific surfaceome markers for Fibroblasts offers several exciting clinical and translational avenues:

• Biomarker Potential: The distinct profiles of surface markers can serve as potential diagnostic or prognostic biomarkers for colon cancer. For instance, high expression of CAF-specific markers like FAP, PDGFRB, or CD276 in biopsy samples could indicate the presence of tumor-promoting Fibroblasts, aiding in early diagnosis or predicting disease aggressiveness.
• Therapeutic Targets: Given that these are surfaceome markers, they are directly accessible for targeted therapies.
• CAF-Targeted Therapies: Markers like FAP, PDGFRB, CD276, and integrins represent promising targets for developing novel anti-cancer therapies that aim to deplete, reprogram, or inhibit the pro-tumorigenic functions of CAFs. This could include antibody-drug conjugates (ADCs), CAR-T cell therapies targeting CAF surface proteins, or small molecule inhibitors against receptor tyrosine kinases like PDGFRB.
• Combination Therapies: Targeting CAFs could enhance the efficacy of existing treatments, such as chemotherapy or immunotherapy, by normalizing the tumor microenvironment and overcoming resistance mechanisms.
• Experimental Validation: These identified markers provide a strong basis for further experimental validation. Techniques like immunohistochemistry (IHC) or immunofluorescence on patient tissue arrays could confirm protein expression patterns. Flow cytometry or mass cytometry could be used to isolate and characterize these distinct Fibroblast populations, allowing for *in vitro* functional studies to dissect their precise roles in tumor progression and test the efficacy of targeted agents.

18. CD4+ T cell Condition-Specific Surfaceome Markers in Colon Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed by CD4+ T cells in Colon tissue, differentiating between "Adj_normal" (adjacent normal) and "Tumor" conditions. The dot plot displays selected genes, representing up to 50 top markers per condition, based on their differential expression and prevalence. The size of each dot indicates the fraction of cells within a given sample expressing the gene, while the color intensity reflects the mean expression level of that gene in those cells. The goal is to uncover distinct surface molecular phenotypes of CD4+ T cells in the healthy colon versus the tumor microenvironment.

Visual Summary

The dot plot effectively stratifies CD4+ T cell samples into two distinct clusters corresponding to the "Adj_normal" and "Tumor" conditions based on their surface marker expression profiles.

• Adj_normal-Specific Markers: A clear cluster of genes, including MYADM, SLC2A3, CD55, PTGER4, and AREG, shows high expression (darker red dots) and a high fraction of expressing cells (larger dots) predominantly in the "Adj_normal" samples (e.g., SMC03-N, SMC07-N, SMC08-N, etc.). These genes are largely absent or expressed at very low levels in "Tumor" samples.
• Tumor-Specific Markers: Conversely, a prominent set of genes demonstrates high expression and prevalence almost exclusively in "Tumor" samples (e.g., SMC24-T, SMC08-T, SMC06-T, etc.). Key markers in this group include immune checkpoint/co-stimulatory molecules like TNFRSF4 (OX40), TNFRSF18 (GITR), TIGIT, and CTLA4. Also notable are MHC Class II molecules such as HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, as well as adhesion/trafficking molecules like ICAM2, ITGB1, CXCR6, CD58. Other markers like IL2RA (CD25) and FAS are also highly expressed in the tumor context.

The horizontal bar plot on the right indicates the number of CD4+ T cells contributing to each sample's data, providing context for the robustness of the marker signals within each sample. The distinct separation of gene expression patterns strongly indicates a significant shift in CD4+ T cell surface phenotype between normal and cancerous colon environments.

Biological Interpretation

The observed condition-specific surfaceome markers reveal distinct biological states and functions of CD4+ T cells in the healthy colon versus the tumor microenvironment.

CD4+ T Cells in Adjacent Normal Colon Tissue

The markers enriched in "Adj_normal" CD4+ T cells likely reflect a homeostatic, quiescent, or steady-state immune surveillance role.

• MYADM (Myeloid-associated differentiation marker): While its role in T cells is less defined than in myeloid cells, its expression might signify specific homeostatic T cell subsets or a regulatory function in the healthy gut [GeneCards].
• SLC2A3 (GLUT3): A high-affinity glucose transporter, typically associated with cells requiring significant glucose for metabolic activity. In quiescent T cells, its expression could indicate a readiness for activation or baseline metabolic activity [GeneCards].
• CD55 (DAF): Protects host cells from complement-mediated damage, suggesting normal immune regulation and protection of bystand cells in a non-inflammatory context [GeneCards].
• PTGER4 (EP4): A prostaglandin E2 receptor, involved in diverse immune responses. In normal tissue, it might contribute to maintaining immune tolerance or modulating local inflammation [GeneCards].
• AREG (Amphiregulin): An EGF receptor ligand, produced by T cells and involved in tissue repair and epithelial proliferation. Its presence might reflect the CD4+ T cells' role in maintaining intestinal barrier integrity and promoting mucosal healing in the normal colon [GeneCards].

CD4+ T Cells in Colon Tumor Microenvironment

The robust expression of specific surface markers in the tumor samples points towards an activated, often exhausted, and highly regulated state of CD4+ T cells, adapting to the suppressive and complex tumor microenvironment.

• Immune Checkpoint & Co-stimulatory Molecules: The most striking finding is the strong upregulation of both co-stimulatory (e.g., TNFRSF4/OX40, TNFRSF18/GITR) and co-inhibitory (e.g., TIGIT, CTLA4) receptors.
• OX40 and GITR are key co-stimulatory molecules upregulated on activated T cells, promoting their survival, proliferation, and effector functions. Their presence indicates ongoing T cell activation, likely in response to tumor antigens [UniProt] [UniProt].
• The simultaneous high expression of TIGIT and CTLA4 is highly indicative of T cell exhaustion or a regulatory T cell (Treg) phenotype. Both are critical immune checkpoint receptors that suppress T cell activation and proliferation, contributing significantly to immune evasion by tumors [UniProt] [UniProt]. This suggests a dysfunctional anti-tumor immune response despite T cell activation.
• MHC Class II Molecules (HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA): While primarily expressed by antigen-presenting cells (APCs), CD4+ T cells can express MHC Class II upon activation or in specific subsets. Their high expression in tumor-infiltrating CD4+ T cells might suggest a specialized subset with potential for self-presentation or interaction with other immune cells in the highly active tumor microenvironment [GeneCards].

Adhesion and Trafficking Molecules (ICAM2, ITGB1, CXCR6, CD58):

• ICAM2 and ITGB1 are involved in cell adhesion and migration, important for T cell trafficking into and within the tumor microenvironment [GeneCards].
• CXCR6 is a chemokine receptor often associated with tissue-resident memory T cells (TRM). Its upregulation suggests the presence of CD4+ TRM cells within the tumor, which can play roles in long-term surveillance or chronic inflammation [UniProt].
• CD58 (LFA-3) interacts with CD2 on other immune cells, mediating adhesion and co-stimulation, critical for robust T cell-APC interactions in the tumor [GeneCards].

Activation/Apoptosis Markers (IL2RA/CD25, FAS, FURIN):

• IL2RA (CD25) is a marker for activated T cells and regulatory T cells (Tregs). Its high expression can denote either a highly activated effector state or an accumulation of Tregs, both prevalent in the TME [UniProt].
• FAS (CD95) is a death receptor. Its upregulation suggests increased susceptibility to apoptosis (e.g., activation-induced cell death) in the tumor, a common feature of T cells in chronic inflammatory or cancer settings [UniProt].
• FURIN is a protease involved in processing various precursor proteins, which could contribute to altered cellular functions or the processing of specific factors in the TME.

Overall, CD4+ T cells in Colon tumors display a phenotype characterized by activation signals, co-inhibitory receptor expression indicative of exhaustion/regulation, and molecules facilitating tissue residence and interaction within a complex immune milieu.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers for CD4+ T cells in Colon cancer has several important clinical and translational implications:

• Biomarker Discovery for Patient Stratification: Genes like TIGIT, CTLA4, OX40, GITR, and IL2RA serve as potential biomarkers. Their expression profiles could be used to stratify patients based on the immune state of their CD4+ T cells, potentially predicting prognosis or response to specific immunotherapies. For instance, high TIGIT/CTLA4 expression might indicate a more immunosuppressive tumor microenvironment.
• Therapeutic Targets for Immunotherapy: The strong presence of immune checkpoint molecules (TIGIT, CTLA4) and co-stimulatory receptors (OX40, GITR) highlights their continued relevance as therapeutic targets.
• Blockade of TIGIT or CTLA4 aims to reverse T cell exhaustion and enhance anti-tumor immunity.
• Agonistic antibodies targeting OX40 or GITR could boost effector CD4+ T cell responses.

This analysis validates these pathways as active in CD4+ T cells within Colon tumors and suggests potential combination strategies.

• Monitoring Immunotherapy Response: Changes in the expression of these surface markers on CD4+ T cells in patient biopsies or peripheral blood (if applicable) could be used to monitor the efficacy of immunotherapy or track disease progression.
• Understanding Tumor Immune Evasion: The co-expression of activation markers with exhaustion markers (e.g., OX40 with TIGIT/CTLA4) suggests a dynamic interplay where T cells are activated but simultaneously suppressed. This provides insight into mechanisms of immune evasion in Colon cancer and informs strategies to overcome resistance to current treatments.
• Experimental Validation and Cell Isolation: These identified surface markers are crucial for experimental validation. They can be used to design flow cytometry panels or for immunomagnetic bead-based sorting to isolate specific CD4+ T cell subsets from patient samples for further functional characterization. This allows researchers to study the precise roles of these phenotypically distinct T cell populations in disease pathogenesis and response to therapy.

19. Dysregulation of Cell Cycle Pathway Genes in Tumor-Associated Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential expression of a curated panel of Cell Cycle pathway-related genes within Intestinal Epithelial cells, comparing tumor (Tumor) and adjacent normal (Adj_normal) conditions. The data, derived from single-cell RNA sequencing of colon tissue, specifically focuses on Intestinal Epithelial cells, which are identified as the tumor origin cell type. The objective is to identify statistically significant changes in gene expression that underscore the molecular mechanisms driving altered cellular proliferation in the tumor microenvironment.

Visual Summary

The box plots display the sample mean gene expression for 24 statistically significant Cell Cycle pathway-related genes. For each gene, expression levels in Intestinal Epithelial cells from the Tumor condition (orange boxes) are compared against those from the Adj_normal condition (blue boxes).

A consistent and striking pattern is observed across all plotted genes:

• Widespread Upregulation in Tumor: Every single gene displayed in the plots exhibits significantly higher expression in the Tumor condition compared to the Adj_normal condition.
• Statistical Significance: All differences are statistically significant, with p-values ranging from p ≤ 0.05 to p ≤ 1e-5, indicating robust and highly confident observations.
• Magnitude of Change: For many genes, the median expression in tumor cells is substantially higher than in adjacent normal cells, suggesting a strong activation of these pathways.
• Reduced Variance in Normal: Expression levels in adjacent normal tissues generally show less variability compared to tumor tissues, where some genes exhibit a wider spread, potentially reflecting cellular heterogeneity or varying degrees of pathway activation within the tumor.

Biological Interpretation

The observed widespread upregulation of Cell Cycle pathway-related genes in Intestinal Epithelial cells within the tumor context is highly congruent with the fundamental hallmarks of cancer, particularly uncontrolled cell proliferation. As Intestinal Epithelial cells are identified as the tumor origin cell type, these findings directly reflect the aberrant molecular programming within the malignant cells.

Specifically, the upregulated genes encompass various critical functions within the cell cycle:

• DNA Replication & Repair: Genes like MCM7, MCM3, MCM4 (Minichromosome Maintenance Complex components, essential for DNA replication initiation) [1], PCNA (Proliferating Cell Nuclear Antigen, a key component of DNA replication machinery) [2], and RAD21 (part of the cohesin complex, crucial for chromosome segregation and DNA repair) [3] are all highly expressed. This indicates increased DNA synthesis and preparatory phases for cell division.

Cell Cycle Progression Regulators:

• Cyclins and CDKs: CCND1, CCND2, CCND3, CCNH, CDK4, CDK6, CDK7 are all upregulated. Cyclins (like CCND1) and Cyclin-Dependent Kinases (CDKs) form complexes that drive cell cycle progression through different phases (e.g., G1 to S phase, G2 to M phase) [4]. Their overexpression is a common oncogenic event.
• Cell Division Cycle (CDC) proteins: CDC16, CDC25B, CDC26, CDC27 are also elevated. These proteins play diverse roles in regulating cell cycle transitions, including activation of CDKs.

Mitotic Apparatus and Checkpoint Components:

• ANAPC1, ANAPC5, ANAPC7, ANAPC10, ANAPC11, ANAPC13 are components of the Anaphase-Promoting Complex (APC/C), a ubiquitin ligase that regulates metaphase-anaphase transition [5]. Their upregulation suggests increased mitotic activity.
• BUB3, MAD2L1, MAD2L2 are involved in the spindle assembly checkpoint (SAC), ensuring proper chromosome segregation [6]. While checkpoints are generally inhibitory, their increased expression might reflect increased mitotic errors or an ongoing, albeit often ineffective, cellular attempt to regulate rapid proliferation.
• TTK (or MPS1) is a key kinase in the SAC, also upregulated.
• WEE1 is a kinase that inhibits CDK1, preventing premature entry into mitosis. Its upregulation might indicate a compensatory mechanism in rapidly dividing cells, attempting to control the pace of division [7].

Transcription Factors and Co-regulators:

• MYC is a potent proto-oncogene, a master regulator of cell growth, proliferation, and apoptosis [8]. Its strong upregulation is a hallmark of many cancers and directly contributes to uncontrolled proliferation.
• E2F4, TFDP1, TFDP2 are components of the E2F transcription factor family, which regulate the expression of genes essential for DNA synthesis and cell cycle progression [9]. Their increased expression points to heightened transcriptional activity favoring proliferation.
• CREBBP and EP300 are histone acetyltransferases involved in transcriptional activation, often dysregulated in cancer [10].
• HDAC1 and HDAC2 are histone deacetylases, frequently overexpressed in tumors and contributing to oncogenesis by altering gene expression [11].

Tumor Suppressors and Associated Regulators:

• TP53 (tumor protein p53) is a critical tumor suppressor. Its upregulation in tumor cells can sometimes indicate accumulation of mutant p53 protein (which often loses its tumor-suppressive function and can even gain oncogenic properties) or an active, but potentially overwhelmed, wild-type p53 response to oncogenic stress [12].
• MDM2 (E3 ubiquitin ligase for p53) is often co-expressed or overexpressed with p53 in cancers, leading to p53 degradation, further promoting proliferation [13].
• RB1 (retinoblastoma 1) and RBL2 (p130) are part of the RB family of tumor suppressor proteins that regulate the G1/S checkpoint [14]. Their increased expression in tumor cells could be a feedback response to dysregulated cell cycle, or could be indicative of mechanisms attempting to compensate for their functional inactivation.
• CDKN1A (p21) and CDKN1B (p27), while CDK inhibitors, can also show complex roles in cancer, sometimes even being associated with tumor progression depending on the cellular context and post-translational modifications [15]. Their upregulation here could be part of an attempt to impose cell cycle arrest, which is overridden by other oncogenic signals.
• 14-3-3 Proteins: Several members of the 14-3-3 family (YWHAB, YWHAQ, YWHAH, YWHAE, YWHAG, YWHAZ) are upregulated. These proteins regulate various cellular processes, including cell cycle progression, DNA damage response, and apoptosis, often by binding to phosphoproteins and modulating their activity, localization, or stability [16]. Their widespread upregulation suggests a broad perturbation of cellular signaling networks.

Taken together, these findings strongly suggest that Intestinal Epithelial cells in the tumor are undergoing significant transcriptional reprogramming to support rapid and unchecked proliferation, a defining characteristic of cancer. The simultaneous upregulation of both pro-proliferative genes and some cell cycle inhibitors or DNA damage response genes highlights the complex and often compensatory mechanisms at play in tumor cells.

Clinical or Translational Implications

The pervasive upregulation of cell cycle-related genes in Intestinal Epithelial cells within colon tumors has several important clinical and translational implications:

• Biomarker Potential: The identified genes could serve as valuable biomarkers for detecting early-stage colon cancer, monitoring disease progression, or predicting response to therapy. Elevated expression of these genes could indicate a more aggressive tumor phenotype.
• Therapeutic Targets: Many of the upregulated genes are established or emerging targets for cancer therapy. For instance:
• CDK inhibitors are widely used or in clinical trials for various cancers [17]. The observed upregulation of CDK4, CDK6, CDK7, CCND1, CCND2, CCND3 suggests that CDK-targeting agents could be relevant in colon cancer.
• MYC inhibitors are under active investigation due to its central role in oncogenesis [18].
• HDAC inhibitors (HDACi) are already approved for some hematological malignancies and are being explored in solid tumors like colon cancer [19].
• WEE1 inhibitors are also in clinical development, aiming to induce mitotic catastrophe in cancer cells [20].
• Targeting specific components of the DNA replication machinery (e.g., MCM proteins) or DNA damage response pathways (e.g., ATM/ATR) represents additional therapeutic avenues.
• Prognostic Value: The extent of upregulation of these cell cycle genes might correlate with tumor grade, stage, or patient outcome, providing prognostic information.
• Personalized Medicine: Understanding the specific cell cycle genes that are most dysregulated in an individual patient's tumor could guide personalized treatment strategies, tailoring therapies to target the most activated proliferative pathways.

References

1. MCM Proteins: GeneCards entry for MCM7. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MCM7
2. PCNA: GeneCards entry for PCNA. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PCNA
3. RAD21: GeneCards entry for RAD21. https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAD21
4. Cyclins and CDKs: PubMed search: "cyclin CDK cancer cell cycle". https://pubmed.ncbi.nlm.nih.gov/?term=cyclin+CDK+cancer+cell+cycle
5. APC/C: PubMed search: "anaphase promoting complex cancer". https://pubmed.ncbi.nlm.nih.gov/?term=anaphase+promoting+complex+cancer
6. Spindle Assembly Checkpoint: PubMed search: "spindle assembly checkpoint cancer". https://pubmed.ncbi.nlm.nih.gov/?term=spindle+assembly+checkpoint+cancer
7. WEE1: GeneCards entry for WEE1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=WEE1
8. MYC: GeneCards entry for MYC. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYC
9. E2F Transcription Factors: PubMed search: "E2F transcription factor cancer". https://pubmed.ncbi.nlm.nih.gov/?term=E2F+transcription+factor+cancer
10. CREBBP/EP300: GeneCards entry for EP300. https://www.genecards.org/cgi-bin/carddisp.pl?gene=EP300
11. HDAC1/HDAC2: PubMed search: "HDAC1 HDAC2 cancer". https://pubmed.ncbi.nlm.nih.gov/?term=HDAC1+HDAC2+cancer
12. TP53: GeneCards entry for TP53. https://www.genecards.org/cgi-bin/carddisp.pl?gene=TP53
13. MDM2: GeneCards entry for MDM2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MDM2
14. RB1/RBL2: GeneCards entry for RB1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=RB1
15. CDKN1A/CDKN1B (p21/p27): PubMed search: "CDKN1A CDKN1B cancer role". https://pubmed.ncbi.nlm.nih.gov/?term=CDKN1A+CDKN1B+cancer+role
16. 14-3-3 Proteins: PubMed search: "14-3-3 proteins cell cycle cancer". https://pubmed.ncbi.nlm.nih.gov/?term=14-3-3+proteins+cell+cycle+cancer
17. CDK Inhibitors in Cancer: PubMed search: "CDK inhibitors cancer therapy". https://pubmed.ncbi.nlm.nih.gov/?term=CDK+inhibitors+cancer+therapy
18. MYC Inhibitors in Cancer: PubMed search: "MYC inhibitors cancer therapy". https://pubmed.ncbi.nlm.nih.gov/?term=MYC+inhibitors+cancer+therapy
19. HDAC Inhibitors in Colon Cancer: PubMed search: "HDAC inhibitors colon cancer". https://pubmed.ncbi.nlm.nih.gov/?term=HDAC+inhibitors+colon+cancer
20. WEE1 Inhibitors in Cancer: PubMed search: "WEE1 inhibitors cancer therapy". https://pubmed.ncbi.nlm.nih.gov/?term=WEE1+inhibitors+cancer+therapy

20. Intestinal Epithelial Cell Gene Ontology Analysis: Diploid vs. Aneuploid and Tumor vs. Adjacent Normal States

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes Gene Ontology (GO) enrichment, specifically Gene Set Analysis (GSA), to identify biological processes and pathways that are significantly upregulated in Intestinal Epithelial cells under different conditions. Two main comparisons are presented:

1. Diploid vs. Others: Upregulated pathways in Intestinal Epithelial cells classified as Diploid (genomically stable) compared to those classified as Aneuploid (genomically unstable). This comparison highlights functions and responses associated with genomic stability in epithelial cells.
2. Tumor vs. Others: Upregulated pathways in Intestinal Epithelial cells from Tumor tissue compared to those from Adjacent Normal tissue. This comparison reveals biological changes specifically driven by the tumor microenvironment and oncogenic processes within the epithelial cells, which are the cells of origin for colorectal cancer.

The results are presented as bar plots, showing the top enriched GO terms ranked by their statistical significance (-log(p-val) and -log(q-val)). The GSA_up designation confirms that these are pathways found to be significantly *upregulated* in the test condition compared to the reference.

Visual Summary

The two bar plots display the top Gene Ontology terms significantly enriched in Intestinal Epithelial cells under the specified comparison groups.

• Diploid_vs_others (Diploid vs. Aneuploid): This plot shows approximately 30 significantly upregulated GO terms in diploid intestinal epithelial cells. The terms primarily relate to fundamental metabolic processes (e.g., "Mineral absorption," "Arginine and proline metabolism," "Nitrogen metabolism," "Fat digestion and absorption"), cell signaling pathways ("PPAR signaling pathway," "Toll-like receptor signaling pathway," "NF-kappa B signaling pathway"), and cellular quality control ("Apoptosis"). Several disease-related terms, including viral infections and various cancers, also appear, indicating underlying biological processes linked to these conditions. The -log(q-val) values are relatively lower compared to the Tumor comparison, suggesting moderate but significant enrichment.
• Tumor_vs_others (Tumor vs. Adjacent Normal): This plot presents a substantially larger number of significantly upregulated GO terms, indicating a more extensive shift in cellular biology in tumor-associated epithelial cells. The terms are highly diverse, with prominent enrichment in processes critical for cellular growth and survival (e.g., "Protein processing in endoplasmic reticulum," "RNA transport," "Spliceosome," "Ribosome," "Cell cycle," "Ubiquitin mediated proteolysis," "Autophagy," "Endocytosis," "Oxidative phosphorylation"). Pathways associated with cellular stress, inflammation, and various diseases, including multiple cancer types, are also highly enriched. Both the -log(p-val) and -log(q-val) values are markedly higher than in the Diploid comparison, signifying stronger and more widespread enrichment.

Biological Interpretation

Intestinal Epithelial Cells: Diploid vs. Aneuploid

This comparison highlights functions that are either maintained or actively upregulated in genomically stable (Diploid) Intestinal Epithelial cells compared to their genomically unstable (Aneuploid) counterparts.

• Metabolic Homeostasis and Absorption: Pathways such as "Mineral absorption," "Arginine and proline metabolism," "Nitrogen metabolism," and "Fat digestion and absorption" are crucial for the normal physiological function of intestinal epithelial cells in nutrient uptake and metabolism. Their upregulation in diploid cells suggests that these fundamental specialized functions are robustly maintained in cells with stable genomes, and potentially compromised in aneuploid cells. The "PPAR signaling pathway" further underscores the regulation of lipid metabolism and inflammation. [GeneCards - PPAR Signaling Pathway: GeneCards]
• Immune Surveillance and Response: "Toll-like receptor signaling pathway" and "NF-kappa B signaling pathway" indicate an active innate immune response and inflammatory signaling capacity in diploid cells. This is consistent with the role of intestinal epithelial cells as a primary barrier and first responder to pathogens in the gut lumen. The presence of terms like "Coronavirus disease," "Epstein-Barr virus infection," and "Kaposi sarcoma-associated herpesvirus infection" could reflect a general capacity for antiviral responses or detection of viral components, rather than active disease, or a role in mediating immune responses in the local microenvironment. [PubMed search - Intestinal epithelial cells innate immunity: PubMed Search]
• Cellular Quality Control: The enrichment of "Apoptosis" suggests that diploid epithelial cells maintain a functional program for programmed cell death. This is a critical mechanism for removing damaged or potentially aberrant cells, thus preventing the accumulation of cells that could contribute to tissue dysplasia or tumorigenesis. This pathway is often dysregulated in cancer cells.
• Disease-Related Pathways: The appearance of various disease terms (e.g., "Colorectal cancer," "Non-small cell lung cancer") in the context of *upregulation* in diploid cells suggests that these cells may be actively engaged in pathways that protect against or respond to the initial stages of disease development, or that some fundamental processes shared with these diseases are under tighter control in healthy, diploid cells.

Intestinal Epithelial Cells: Tumor vs. Adjacent Normal

This comparison identifies biological processes that are significantly elevated in Intestinal Epithelial cells within the tumor microenvironment compared to those in adjacent normal tissue. These reflect key hallmarks of cancer development and progression.

• Elevated Biosynthesis and Metabolic Reprogramming: A striking feature is the upregulation of pathways related to protein synthesis, processing, and degradation, including "Protein processing in endoplasmic reticulum," "RNA transport," "Spliceosome," "Ribosome," "Ubiquitin mediated proteolysis," and "Proteasome." These pathways collectively indicate an intensely active cellular machinery geared towards rapid growth, proliferation, and adaptation to the oncogenic environment, hallmarks of cancer cells. [PubMed search - Cancer cell metabolism protein synthesis: PubMed Search]
• Uncontrolled Proliferation: The strong enrichment of "Cell cycle" directly points to the uncontrolled and accelerated proliferation characteristic of tumor cells.
• Cellular Stress and Survival Mechanisms: Pathways like "Autophagy" and "Endocytosis" are often upregulated in cancer cells to recycle cellular components and acquire nutrients, enabling survival under nutrient deprivation or metabolic stress. "Oxidative phosphorylation" indicates increased energy production, reflecting high metabolic demands of rapidly dividing cells. The presence of "Protein processing in endoplasmic reticulum" can also signify ER stress, a common feature in rapidly growing tumors with high protein synthesis demands.
• Dysregulated Signaling: Enrichment of "mTOR signaling pathway" and "AMPK signaling pathway" highlights the significant dysregulation of cellular growth, metabolism, and energy sensing pathways, which are frequently hijacked by cancer cells to promote their survival and proliferation. [GeneCards - mTOR: GeneCards], [GeneCards - AMPK: GeneCards]

Complex Cellular Responses and Disease Associations:

• Neurodegeneration pathways (e.g., "Alzheimer disease," "Parkinson disease," "Huntington disease"): While seemingly unrelated to colon cancer, these pathways often involve protein misfolding, aggregation, and cellular stress responses. Their upregulation here might indicate a generalized cellular stress response, protein quality control issues, or shared molecular mechanisms of cellular dysfunction within tumor cells.
• "Cellular senescence": Although often initially tumor-suppressive, senescent cells within tumors can acquire a senescence-associated secretory phenotype (SASP), contributing to chronic inflammation, immune evasion, and tumor progression. [PubMed search - Cellular senescence cancer progression: PubMed Search]
• Infection and Immune Response: "Salmonella infection," "Human T-cell leukemia virus 1 infection," and "Human papillomavirus infection" alongside others suggest altered immune responses or interactions with pathogens within the tumor microenvironment. "Epithelial cell signaling in Helicobacter pylori infection" can indicate activation of inflammatory pathways also relevant in gastric cancer. This points to the complex interplay between the host immune system, microbiome, and cancer progression.
• "Tight junction": Dysregulation of tight junctions is common in epithelial cancers, contributing to loss of barrier function and increased invasiveness. [PubMed search - Tight junction colon cancer: PubMed Search]

Clinical or Translational Implications

The Gene Ontology analysis of Intestinal Epithelial cells provides crucial insights into the fundamental biological shifts occurring during colorectal cancer development and progression.

1. Biomarker Discovery: The distinct sets of pathways upregulated in diploid vs. aneuploid cells and tumor vs. adjacent normal cells could provide potential biomarkers. For instance, genes within the "Mineral absorption" or "Toll-like receptor signaling pathway" might serve as indicators of healthy epithelial function, while highly enriched tumor pathways like "Cell cycle," "mTOR signaling," or "Protein processing in endoplasmic reticulum" could be used to identify malignant transformation or predict tumor aggressiveness.
2. Therapeutic Targeting: The extensive upregulation of pathways related to cell cycle progression, protein synthesis, cellular stress, and metabolic reprogramming in tumor epithelial cells highlights several well-established targets for cancer therapy.

• Cell Cycle: Direct targeting of cell cycle regulators could inhibit tumor proliferation.
• Protein Homeostasis: Inhibitors of protein synthesis (e.g., specific ribosomes or ER stress pathways) or degradation (proteasome inhibitors) could selectively impact rapidly growing cancer cells.
• Metabolic Rewiring: Modulating pathways like mTOR, AMPK, or oxidative phosphorylation could starve cancer cells of energy or nutrients.
• Autophagy/Endocytosis: Manipulating these processes could disrupt tumor cell survival mechanisms, particularly in stressed microenvironments.

3. Understanding Etiology and Microenvironment: The enrichment of various infection-related pathways in both comparisons suggests a role for the host-pathogen interaction and inflammation in shaping the epithelial cell state, whether healthy or cancerous. This underscores the importance of the gut microbiome and immune responses in colorectal cancer pathogenesis and could inform strategies involving immunomodulation or microbiome-targeted therapies.
4. Genomic Instability as a Driver: The comparison between diploid and aneuploid cells underscores that genomic stability is linked to the maintenance of normal epithelial functions and quality control. Loss of diploidy and subsequent genomic instability may lead to a dysfunctional state that is permissive for or contributes to tumorigenesis. Investigating genes and pathways that differentiate these states could identify early drivers of malignant transformation.

21. Colon Cancer Microenvironment: Gene Set Enrichment Analysis across Major Cell Types

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot, investigating pathway activity differences in major cell types from human colon tissue under "Tumor" and "Adj_normal" conditions. For Intestinal Epithelial cells (the identified tumor origin cell type), an additional comparison based on ploidy (Diploid vs. others, likely Aneuploid) is included. Each dot represents a specific pathway's enrichment status (Normalized Enrichment Score, NES, indicated by color) and statistical significance (-log(P-value), indicated by dot size) for a given cell type under a particular condition compared to other conditions (e.g., "Tumor vs. others" means Tumor condition compared to Adj_normal, and vice-versa). The RdBu_r colormap is used, where red indicates positive enrichment (upregulation of genes in the pathway) and blue indicates negative enrichment (downregulation).

Visual Summary

The dot plot effectively summarizes a large number of GSEA results across various cell types and conditions.

• X-axis: Represents the "Cases," which are combinations of major cell types (B cell, Endothelial cell, Fibroblast, ILC, Intestinal Epithelial cell, Macrophage, Plasma cell, T cell CD4+, T cell CD8+) and comparison conditions ("Adj_normal_vs_others", "Tumor_vs_others", and for Intestinal Epithelial cells, "Diploid_vs_others").
• Y-axis: Lists 80 significantly enriched or depleted pathways, primarily from metabolic, immune, and cancer-related categories.
• Dot Color (NES): A robust red-to-blue gradient indicates the Normalized Enrichment Score. Red signifies pathways with genes predominantly upregulated in the test condition relative to the reference, while blue signifies pathways with genes predominantly downregulated. Deeper colors indicate stronger enrichment/depletion.
• Dot Size (-log(P)): The size of the dot corresponds to the statistical significance of the enrichment, with larger dots indicating more significant p-values (e.g., -log(P) = 30 is highly significant).

Overall, there's a clear pattern of inverse enrichment for many pathways between "Adj_normal_vs_others" and "Tumor_vs_others" within the same cell type, as expected. Immune-related pathways often show strong positive enrichment (red, high activity) in immune cells from "Adj_normal" tissue and corresponding negative enrichment (blue, reduced activity) in immune cells from "Tumor" tissue. Conversely, pathways associated with cell proliferation and altered metabolism are frequently positively enriched in tumor-associated cells across multiple cell types.

Biological Interpretation

Hallmarks of Cancer Metabolism and Proliferation in Tumor Microenvironment

Several pathways consistently show strong positive enrichment in cells from the "Tumor_vs_others" condition across multiple cell types, including the tumor-originating Intestinal Epithelial cells, Fibroblasts, Endothelial cells, Macrophages, T cells, B cells, and Plasma cells. This indicates a widespread metabolic reprogramming and increased proliferative activity within the tumor microenvironment (TME).

• Glycolysis: Universally enriched (red, often large dots) in nearly all cell types in the "Tumor_vs_others" comparisons. This is a classic hallmark of cancer (Warburg effect), where cells preferentially use glycolysis even in the presence of oxygen to support rapid proliferation PubMed search: Warburg effect cancer. Its prevalence in both cancer cells and associated stromal/immune cells highlights the metabolic rewiring of the entire TME.
• DNA Replication: Consistently enriched (red, large dots) in tumor-associated Intestinal Epithelial cells, Fibroblasts, Endothelial cells, Macrophages, T cells, B cells, and Plasma cells. This indicates active cell division and expansion, reflecting not only the proliferation of cancer cells but also the recruitment and proliferation of stromal and immune components within the growing tumor.
• Cholesterol Metabolism: Enriched (red) in many cell types in the "Tumor_vs_others" context. Altered lipid metabolism, including cholesterol synthesis and uptake, is increasingly recognized as critical for cancer cell growth, survival, and membrane synthesis PubMed search: Cholesterol metabolism cancer progression.

Immune Dysregulation and Evasion in the Tumor Microenvironment

Immune cell populations (B cells, Macrophages, T cells CD4+, T cells CD8+, ILCs, Plasma cells) exhibit marked differences in pathway activity between adjacent normal and tumor tissue, suggestive of immune suppression and evasion mechanisms within the TME.

• Depletion of Immune Activation Pathways in Tumor-Associated Immune Cells: Pathways like "Antigen processing and presentation," "T cell receptor signaling pathway," "TNF signaling pathway," "JAK-STAT signaling pathway," and "Toll-like receptor signaling pathway" show strong positive enrichment (red) in these immune cells from "Adj_normal_vs_others" but are consistently depleted (blue) or less active in their "Tumor_vs_others" counterparts. This suggests a functional exhaustion, anergy, or M2-like polarization (for macrophages) of immune cells within the tumor, contributing to immune escape PubMed search: T cell exhaustion cancer.
• PD-L1 Expression and PD-1 Checkpoint Pathway: Notably, this pathway is significantly enriched (red, large dot) in CD4+ T cells from the "Tumor_vs_others" condition. This is a critical immune checkpoint axis that, when activated, suppresses T cell activity and is a major mechanism of immune evasion in cancer. The enrichment in tumor-associated CD4+ T cells highlights the activation of this inhibitory pathway, potentially by tumor cells or other TME components. GeneCards: PDCD1, GeneCards: CD274 (PD-L1).

Stromal Remodeling and Endothelial Reprogramming

Fibroblasts and Endothelial cells also demonstrate distinct pathway shifts in the tumor context:

• Fibroblasts: "ECM-receptor interaction" is enriched in "Adj_normal_vs_others" fibroblasts but depleted in "Tumor_vs_others" fibroblasts, suggesting a shift in ECM composition or how fibroblasts interact with it. Tumor-associated fibroblasts (CAFs) are known to be highly active in remodeling the ECM, which can impact this. The enrichment of "Glycolysis," "DNA replication," and "Cholesterol metabolism" in tumor fibroblasts indicates their active role in supporting tumor growth.
• Endothelial Cells: Similar to fibroblasts, "ECM-receptor interaction" and "Cell adhesion molecules" are enriched in "Adj_normal_vs_others" but depleted in "Tumor_vs_others" endothelial cells. However, tumor endothelial cells show strong enrichment for "Glycolysis," "DNA replication," and "Fatty acid degradation," consistent with active angiogenesis and metabolic adaptations required for supporting tumor vascularization PubMed search: Angiogenesis cancer metabolism.

Ploidy-Specific Differences in Intestinal Epithelial Cells

The "Intestinal Epithelial cell: Diploid_vs_others" comparison (presumably Diploid vs. Aneuploid within the tumor context) reveals interesting insights into the tumor origin cell type.

• Diploid Intestinal Epithelial cells show strong positive enrichment for "DNA replication," "Cytosolic DNA-sensing pathway," "Glutathione metabolism," "Glycolysis," and "Pathways in cancer." This could suggest that diploid epithelial cells, even within the tumor, are highly metabolically active and proliferative. These might represent early-stage transformed cells, cells undergoing reactive hyperplasia, or specific "stem-like" tumor cells that maintain diploidy longer, or a subset of non-transformed proliferating epithelial cells adjacent to or within the tumor. This finding warrants further investigation into the distinct biological roles of diploid vs. aneuploid tumor epithelial cells in colon cancer progression.

Clinical or Translational Implications

The GSEA results highlight several potential clinical and translational implications for colon cancer:

• Metabolic Reprogramming as Therapeutic Targets: The pervasive enrichment of "Glycolysis" and "Cholesterol metabolism" across diverse tumor-associated cell types suggests that targeting these metabolic pathways (e.g., with glycolysis inhibitors or cholesterol synthesis inhibitors) could be a broad therapeutic strategy affecting both cancer cells and their supportive stromal/immune microenvironment.
• Immune Checkpoint Blockade: The enrichment of the "PD-L1 expression and PD-1 checkpoint pathway" in tumor-associated CD4+ T cells strongly supports the rationale for PD-1/PD-L1 axis blockade in colon cancer, which aims to reactivate exhausted T cells. Understanding the specific cell types expressing these components and their functional state could further refine immunotherapy strategies.
• Microenvironment-Targeted Therapies: The metabolic and proliferative shifts observed in fibroblasts and endothelial cells underscore the importance of targeting the tumor microenvironment in addition to cancer cells. Strategies aimed at inhibiting CAF activation or anti-angiogenic therapies could complement direct anti-cancer treatments.
• Biomarkers of Progression and Response: The distinct pathway signatures in tumor vs. adjacent normal tissues, and even ploidy-specific signatures within the tumor origin cell type, could yield novel biomarkers for disease progression, prognosis, or response to specific therapies. For instance, the differential activity of "DNA replication" or "Glycolysis" pathways could serve as indicators of tumor aggressiveness or metabolic vulnerability.
• Understanding Early Transformation: The unique activity patterns in diploid Intestinal Epithelial cells (the tumor origin cell type) suggest distinct biological processes. Investigating these pathways further could provide insights into early transformation events and mechanisms preventing aneuploidy, potentially revealing targets for chemoprevention or early intervention.

22. Discussion

The single-cell RNA-seq analysis of colon tissue reveals a dynamic and significantly altered microenvironment in colon cancer compared to adjacent normal tissue. A central finding is the prominent expansion of Intestinal Epithelial cells within tumors, largely characterized by aneuploidy and recurrent genomic amplifications, notably affecting the EGFR gene on chromosome 7 and regions on 19q. These malignant epithelial cells not only exhibit unchecked proliferation, evidenced by widespread upregulation of cell cycle genes, but also orchestrate a complex pro-tumorigenic and immunosuppressive milieu.

The immune landscape is dramatically reprogrammed in the tumor. We observed a general reduction in T cell populations, specifically decreases in cytotoxic T cells (T_Cyto), ILC1s, and LTI cells, which are crucial for anti-tumor immunity and lymphoid tissue development. Conversely, immunosuppressive T cell subsets such as regulatory T cells (Tregs) and Th17 cells are significantly enriched. Macrophages in the tumor microenvironment undergo a striking polarization shift, with a substantial increase in pro-tumorigenic M2B macrophages and a decrease in M2A macrophages. This immune dysregulation is further compounded by altered cell-cell interactions. Aneuploid Intestinal Epithelial cells, macrophages, and T cells engage in numerous inhibitory immune checkpoint interactions, including CD86-CTLA4, LGALS9-HAVCR2 (TIM-3), PVR-TIGIT, and notably, HLA-F-LILRB1 between tumor epithelial cells and CD8+ T cells, highlighting multiple pathways for T cell exhaustion and immune evasion. The PD-L1 expression and PD-1 checkpoint pathway is also enriched in tumor-associated CD4+ T cells, underscoring this critical immune evasion axis.

Stromal cells, particularly fibroblasts, also undergo profound changes, adopting a cancer-associated fibroblast (CAF) phenotype characterized by specific surface markers (e.g., FAP, PDGFRB, CD276) and extensive extracellular matrix (ECM) remodeling. This remodeling, dominated by collagen-integrin interactions in the tumor, contributes to desmoplasia, which can physically impede immune cell infiltration and promote tumor growth and invasion. Furthermore, a global metabolic rewiring is evident across multiple tumor-associated cell types, including epithelial, stromal, and immune cells, with pervasive enrichment of glycolysis and altered cholesterol metabolism, consistent with the high energetic and biosynthetic demands of the proliferating tumor and its supportive microenvironment.

Intriguingly, Gene Ontology analysis reveals that even diploid Intestinal Epithelial cells within tumor samples show an upregulation of pathways often associated with cancer, suggesting that immune evasion and proliferative signals may be engaged early in tumor development. This extensive characterization of cellular populations, genomic alterations, intercellular communication, and metabolic shifts provides a comprehensive understanding of the complex biology underlying colon cancer progression and offers a rich resource for identifying therapeutic vulnerabilities.

Hypotheses:

1. The colon cancer microenvironment actively promotes immune evasion by enriching immunosuppressive T cell subsets (Tregs, Th17) and M2B-polarized macrophages, while simultaneously upregulating inhibitory immune checkpoints (CTLA4, TIGIT, TIM-3, HLA-F-LILRB1) on both tumor and immune cells.
2. Recurrent genomic alterations, particularly EGFR amplification on chromosome 7 and 19q amplification, in aneuploid Intestinal Epithelial cells directly drive their uncontrolled proliferation, metabolic reprogramming, and enhanced pro-tumorigenic cell-cell interactions (e.g., SPP1-integrin axis).
3. Cancer-associated fibroblasts (CAFs) undergo a profound phenotypic shift, characterized by specific surface markers (FAP, PDGFRB, CD276) and extensive ECM remodeling via collagen-integrin interactions, which creates a physically restrictive and signaling-supportive environment that promotes tumor growth and immune exclusion.
4. The 'Warburg effect' (glycolysis) and altered cholesterol metabolism are not restricted to tumor cells but are pervasive across the entire tumor microenvironment (fibroblasts, endothelial, immune cells), indicating a coordinated metabolic rewiring that fuels tumor progression.
5. Immune evasion mechanisms may be initiated early in colon tumorigenesis, even in diploid Intestinal Epithelial cells within the tumor context, potentially preceding widespread aneuploidy and overt malignancy, as evidenced by their engagement in immune checkpoint interactions.
6. The increased Th17 cell population in tumors, despite a general immunosuppressive environment, suggests a context-dependent pro-tumorigenic inflammatory role in colon cancer, possibly by promoting angiogenesis or modulating epithelial cell behavior.

Potential therapeutic targets:

1. EGFR (Epidermal Growth Factor Receptor): EGFR signaling is a well-established oncogenic driver. This analysis identifies recurrent amplification of EGFR-containing regions on chromosome 7 in aneuploid tumor epithelial cells and highlights strong HBEGF-EGFR/EGF-EGFR interactions, particularly between macrophages and aneuploid intestinal epithelial cells. This suggests an activated EGFR pathway promoting tumor cell proliferation and survival within the tumor microenvironment. Evidence: CNV analysis shows high-frequency (0.59) amplification of 7p14.1-7p11.2 and 7p12.3-7q11.23, containing EGFR. Cell-cell interaction (CCI) analysis reveals prominent HBEGF-EGFR and EGF-EGFR interactions in the tumor condition. Intestinal epithelial cells in tumors show widespread upregulation of cell cycle and proliferative pathways. Validation: Evaluate the efficacy of existing EGFR inhibitors (e.g., cetuximab, panitumumab) in patient-derived organoids (PDOs) or xenograft models derived from colon tumors with confirmed EGFR amplification. Assess their impact on tumor cell proliferation, survival, and downstream signaling pathways. Investigate combinations with therapies targeting macrophage-secreted EGFR ligands.
2. SPP1 (Osteopontin) / CD44 axis: The SPP1-CD44 axis is critically involved in pro-tumorigenic signaling, promoting cell survival, invasion, metastasis, and orchestrating an immunosuppressive microenvironment by polarizing macrophages. This analysis shows strong SPP1-integrin self-interactions in aneuploid tumor epithelial cells and robust SPP1-CD44 interactions with macrophages, indicating a key communication pathway supporting tumor progression. Evidence: Cell-cell interaction (CCI) analysis prominently features SPP1-integrin and SPP1-CD44 interactions involving aneuploid intestinal epithelial cells and macrophages in the tumor context. Macrophages in the tumor microenvironment exhibit a shift towards pro-tumorigenic M2B polarization and upregulation of markers like TREM2 and CCL2. Validation: Develop or utilize neutralizing antibodies or small molecules against SPP1 or CD44. Test their ability to disrupt tumor cell adhesion/migration and to reprogram macrophage polarization from M2B-like to M1-like phenotypes in vitro. In vivo, assess the impact of blocking this axis on tumor growth, metastasis, and immune cell infiltration in preclinical models of colon cancer.
3. Immune Checkpoints: TIGIT, CTLA4, HAVCR2 (TIM-3), LILRB1: The tumor microenvironment exhibits extensive and active inhibitory immune checkpoint pathways, leading to T cell exhaustion and immune evasion. Several interactions involving these receptors are prominent between tumor epithelial cells, macrophages, and T cells, signifying multiple mechanisms of immune suppression that can be therapeutically exploited. Evidence: Cell-cell interaction (CCI) analysis demonstrates significant CD86-CTLA4, LGALS9-HAVCR2 (TIM-3), and PVR-TIGIT interactions between macrophages/epithelial cells and T cells. A strong HLA-F-LILRB1 interaction is also noted between aneuploid intestinal epithelial cells and CD8+ T cells. CD4+ T cells in the tumor microenvironment upregulate TIGIT and CTLA4 surface markers. GSEA indicates enrichment of the PD-L1 expression and PD-1 checkpoint pathway in tumor CD4+ T cells. Validation: Administer blocking antibodies against TIGIT, CTLA4, TIM-3, or LILRB1 (individually or in combination, potentially with anti-PD-1/PD-L1) in preclinical colon cancer models. Evaluate the restoration of T cell proliferation, cytokine production, and cytotoxic function, and assess their impact on tumor growth and progression. Conduct ex vivo assays with patient-derived T cells to measure functional restoration upon blockade.
4. FAP (Fibroblast Activation Protein): Cancer-associated fibroblasts (CAFs) are critical components of the tumor stroma, promoting tumor growth, invasion, and immune suppression through ECM remodeling. FAP is a highly specific and reliable surface marker for CAFs across various solid tumors, including colon cancer, making it an attractive target for depleting or reprogramming pro-tumorigenic fibroblasts. Evidence: Dot plot analysis of fibroblast condition-specific markers reveals FAP as a highly upregulated and prevalent surface marker specifically in tumor-associated fibroblasts, with minimal expression in adjacent normal tissue. Condition-specific CCI analysis shows extensive collagen-integrin interactions in tumor samples, indicative of CAF-driven ECM remodeling. Validation: Utilize FAP-targeted therapeutic strategies, such as antibody-drug conjugates (ADCs) or FAP-specific CAR-T cells, in preclinical models of colon cancer. Evaluate the impact on stromal desmoplasia, tumor growth, and immune cell infiltration. Assess whether FAP targeting sensitizes tumors to chemotherapy or immunotherapy.

Follow-up validation ideas:

1. Use multi-modal imaging techniques (e.g., spatial transcriptomics, multiplex immunofluorescence, mass cytometry) on colon cancer tissue sections to spatially map the localization of specific cell subsets (e.g., Tregs, M2B macrophages, CAFs) and their identified surface markers (e.g., TIGIT, CTLA4, TREM2, FAP). This would confirm direct cell-cell contact and validate the physical proximity of interacting ligand-receptor pairs (e.g., SPP1-CD44, HLA-F-LILRB1).
2. Perform in vitro co-culture experiments using patient-derived organoids (PDOs) or primary tumor epithelial cells (categorized by ploidy status) with isolated immune cells (T cells, macrophages) and fibroblasts from adjacent normal and tumor tissues. Assess the functional consequences of identified cell-cell interactions by applying blocking antibodies (anti-SPP1, anti-CD44, anti-LILRB1, anti-TIGIT, anti-TIM-3, anti-CTLA4) or small molecule inhibitors (e.g., EGFR, CDK, glycolytic inhibitors). Measure changes in cell proliferation, migration, immune cell activation/suppression, and macrophage polarization.
3. Conduct CRISPR/shRNA-mediated genetic perturbations of key genes (e.g., SPP1, EGFR, FAP, CTLA4) in patient-derived tumor epithelial cells, CAFs, or immune cells. Analyze the impact of these genetic modifications on their proliferation, invasion, metabolic profiles, and ability to modulate immune responses in co-culture or in vivo xenograft models.
4. Validate prognostic or predictive biomarkers (e.g., high M2B macrophage proportion, specific T cell subset ratios, EGFR amplification status, or specific surface markers like CEACAM1, SDC1, TREM2, FAP) in independent, larger, and ethnically diverse colon cancer patient cohorts using orthogonal methods such as bulk RNA-seq, immunohistochemistry (IHC), flow cytometry, or quantitative PCR.
5. Perform functional assays to assess T cell effector function (cytokine production, cytotoxicity, proliferation) and macrophage phagocytic/antigen presentation capabilities in response to tumor cells or TME components, with and without targeting identified immune checkpoints or pro-tumorigenic ligands. This can involve T cell activation assays, cytokine profiling, and cytotoxicity assays.
6. Utilize genetically engineered mouse models (GEMMs) of colon cancer to specifically deplete or activate identified cell populations (e.g., M2B macrophages, Tregs, CAFs) or pathways (e.g., SPP1-CD44, EGFR) and evaluate the impact on tumor initiation, growth, metastasis, and response to standard or experimental therapies.

Limitations:

This analysis relies on single-cell RNA sequencing data, providing transcriptomic insights that require further validation at the protein level (e.g., for surface markers and cell-cell interactions). Copy number variation (CNV) inference from scRNA-seq, while informative, may have limitations in resolution compared to dedicated genomic sequencing methods. Cell-cell interaction predictions from CellPhoneDB are inferred based on ligand-receptor expression and necessitate experimental validation to confirm functional consequences. The observational nature of the data limits direct inference of causality. While efforts were made to mitigate batch effects, some residual technical variability might persist. Furthermore, the generalizability of these findings to all colon cancer subtypes, stages, and diverse patient populations requires validation through larger, independent cohorts and functional studies. The complex and interconnected nature of the tumor microenvironment means that targeting a single pathway or cell type may have pleiotropic effects.

23. Query List

1. Show UMAPs colored by condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset, arranged in 2 columns and save.
2. Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
3. Filter for tumor-origin cells and unassigned cells, group by sample, show CNV heatmap, and include a summary of significantly amplified regions. Save.
4. Show CNV patterns on UMAP, including major cell type, minor cell type, ploidy results, condition, and sample, arranged in 2 columns and save.
5. Show a population bar plot for minor cell types and save.
6. Show a subset population bar plot for T cells and save.
7. Show a subset population bar plot for Macrophages and save.
8. Show box plots for statistically significant differences in T cell subset populations between conditions, adjusting ncols appropriately based on the total number of panels, and save.
9. Show box plots for statistically significant differences in Macrophage subset populations between conditions, adjusting ncols appropriately based on the total number of panels, and save.
10. Filter for tumor-origin cells and unassigned cells, show their ploidy population as a bar plot and save.
11. Show cell-cell interaction patterns by condition, focusing on tumor-origin cells (Intestinal Epithelial cell), fibroblasts, macrophages, and T cells. Show up to 80 interactions per condition and save.
12. Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
13. Show cell-cell interactions for genes related to immune checkpoint and cell cycle pathways. Save.
14. Find statistically significant differences in cell-cell interactions for major immune and stromal cells between conditions, show as a dot plot, set max_n_items_per_group=25, and save.
15. Show the condition-specific markers for tumor-origin cells (Intestinal Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
16. Extract condition-specific markers for Macrophages and show as a dot plot. Show only surfaceome markers, up to 50 per condition, and save.
17. Extract condition-specific markers for Fibroblasts and show as a dot plot. Show only surfaceome markers, up to 50 per condition, and save.
18. Extract condition-specific markers for T cell CD4+ and show as a dot plot. Show only surfaceome markers, up to 50 per condition, and save.
19. Show box plots for statistically significant differences in expression of Cell cycle pathway-related genes in disease-relevant cells (Intestinal Epithelial cell) between conditions. Set max_n_items_to_plot = 24, adjust ncols to maintain an approximate 2x3 aspect ratio for the overall panel, and save.
20. Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
21. Show Gene set enrichment analysis results as a dot plot for major cell types. Use RdBu_r for the color map, set n_pws_to_show = 80, and save.